WO2012163790A1 - Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as bace1 and/or bace2 inhibitors - Google Patents
Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as bace1 and/or bace2 inhibitors Download PDFInfo
- Publication number
- WO2012163790A1 WO2012163790A1 PCT/EP2012/059688 EP2012059688W WO2012163790A1 WO 2012163790 A1 WO2012163790 A1 WO 2012163790A1 EP 2012059688 W EP2012059688 W EP 2012059688W WO 2012163790 A1 WO2012163790 A1 WO 2012163790A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- difluoro
- chroman
- amino
- oxazine
- amine
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 276
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 40
- 238000011321 prophylaxis Methods 0.000 claims abstract description 37
- 238000004519 manufacturing process Methods 0.000 claims abstract description 33
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 31
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 31
- 239000013543 active substance Substances 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 claims description 179
- 229910052739 hydrogen Inorganic materials 0.000 claims description 68
- 239000001257 hydrogen Substances 0.000 claims description 68
- 238000000034 method Methods 0.000 claims description 54
- 229910052736 halogen Inorganic materials 0.000 claims description 53
- 150000002367 halogens Chemical class 0.000 claims description 43
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 27
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 25
- 206010012601 diabetes mellitus Diseases 0.000 claims description 25
- 150000002431 hydrogen Chemical class 0.000 claims description 25
- CJKPKVLFYAXEBS-UHFFFAOYSA-N 2,3,6,7-tetrahydrooxazepine Chemical compound C1CC=CCNO1 CJKPKVLFYAXEBS-UHFFFAOYSA-N 0.000 claims description 24
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 22
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 21
- 125000003118 aryl group Chemical group 0.000 claims description 18
- 125000001072 heteroaryl group Chemical group 0.000 claims description 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 18
- GZPHSAQLYPIAIN-UHFFFAOYSA-N 3-pyridinecarbonitrile Chemical compound N#CC1=CC=CN=C1 GZPHSAQLYPIAIN-UHFFFAOYSA-N 0.000 claims description 17
- 125000001424 substituent group Chemical group 0.000 claims description 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 13
- 208000037259 Amyloid Plaque Diseases 0.000 claims description 11
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 8
- 208000037765 diseases and disorders Diseases 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229910052721 tungsten Inorganic materials 0.000 claims description 3
- ILDUVQWKATXBRK-LWMIZPGFSA-N (4r)-6',6'-difluoro-2-phenyl-6-pyrimidin-5-ylspiro[2,3-dihydrochromene-4,5'-2,7-dihydro-1,4-oxazepine]-3'-amine Chemical compound FC1(F)COCC(N)=N[C@]11C2=CC(C=3C=NC=NC=3)=CC=C2OC(C=2C=CC=CC=2)C1 ILDUVQWKATXBRK-LWMIZPGFSA-N 0.000 claims description 2
- YDDDHEKSPHYAQB-SYIFMXBLSA-N (4r)-6-(3,5-dichlorophenyl)-6',6'-difluoro-2-phenylspiro[2,3-dihydrochromene-4,5'-2,7-dihydro-1,4-oxazepine]-3'-amine Chemical compound FC1(F)COCC(N)=N[C@]11C2=CC(C=3C=C(Cl)C=C(Cl)C=3)=CC=C2OC(C=2C=CC=CC=2)C1 YDDDHEKSPHYAQB-SYIFMXBLSA-N 0.000 claims description 2
- XCYHTTBEKBBTRX-JFGZAKSSSA-N (4r)-6-(5-chloropyridin-3-yl)-6',6'-difluoro-2-phenylspiro[2,3-dihydrochromene-4,5'-2,7-dihydro-1,4-oxazepine]-3'-amine Chemical compound FC1(F)COCC(N)=N[C@]11C2=CC(C=3C=C(Cl)C=NC=3)=CC=C2OC(C=2C=CC=CC=2)C1 XCYHTTBEKBBTRX-JFGZAKSSSA-N 0.000 claims description 2
- HTYLBGHMBZHPQA-XSWBTSGESA-N 3-[(4r)-3'-amino-6',6'-difluoro-2-phenylspiro[2,3-dihydrochromene-4,5'-2,7-dihydro-1,4-oxazepine]-6-yl]benzonitrile Chemical compound FC1(F)COCC(N)=N[C@]11C2=CC(C=3C=C(C=CC=3)C#N)=CC=C2OC(C=2C=CC=CC=2)C1 HTYLBGHMBZHPQA-XSWBTSGESA-N 0.000 claims description 2
- WKHCMRQWFIJRPW-SYIFMXBLSA-N 5-[(4r)-3'-amino-6',6'-difluoro-2-phenylspiro[2,3-dihydrochromene-4,5'-2,7-dihydro-1,4-oxazepine]-6-yl]pyridine-3-carbonitrile Chemical compound FC1(F)COCC(N)=N[C@]11C2=CC(C=3C=C(C=NC=3)C#N)=CC=C2OC(C=2C=CC=CC=2)C1 WKHCMRQWFIJRPW-SYIFMXBLSA-N 0.000 claims description 2
- BVHQFJQCHQRJAB-MQNHUJCZSA-N n-[(4r)-3'-amino-6',6'-difluoro-2-phenylspiro[2,3-dihydrochromene-4,5'-2,7-dihydro-1,4-oxazepine]-6-yl]-5-(trifluoromethyl)pyridine-2-carboxamide Chemical compound FC1(F)COCC(N)=N[C@]11C2=CC(NC(=O)C=3N=CC(=CC=3)C(F)(F)F)=CC=C2OC(C=2C=CC=CC=2)C1 BVHQFJQCHQRJAB-MQNHUJCZSA-N 0.000 claims description 2
- BKNMAWSXNQABER-NRWPOFLRSA-N n-[(4r)-3'-amino-6',6'-difluoro-2-phenylspiro[2,3-dihydrochromene-4,5'-2,7-dihydro-1,4-oxazepine]-6-yl]-5-cyanopyridine-2-carboxamide Chemical compound FC1(F)COCC(N)=N[C@]11C2=CC(NC(=O)C=3N=CC(=CC=3)C#N)=CC=C2OC(C=2C=CC=CC=2)C1 BKNMAWSXNQABER-NRWPOFLRSA-N 0.000 claims description 2
- 229910052720 vanadium Inorganic materials 0.000 claims description 2
- 229910052727 yttrium Inorganic materials 0.000 claims description 2
- ZBPYOEMMLMVVQT-UHFFFAOYSA-N 5-chloropyridine-2-carboxamide Chemical compound NC(=O)C1=CC=C(Cl)C=N1 ZBPYOEMMLMVVQT-UHFFFAOYSA-N 0.000 claims 1
- 102100021277 Beta-secretase 2 Human genes 0.000 abstract description 32
- 101000894883 Homo sapiens Beta-secretase 2 Proteins 0.000 abstract description 31
- 102100021257 Beta-secretase 1 Human genes 0.000 abstract description 25
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 abstract description 23
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 239000000543 intermediate Substances 0.000 description 285
- 238000001819 mass spectrum Methods 0.000 description 152
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 123
- 239000007787 solid Substances 0.000 description 109
- 239000000047 product Substances 0.000 description 107
- -1 hydrocarbon radical Chemical class 0.000 description 105
- 239000000203 mixture Substances 0.000 description 71
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 66
- 239000000243 solution Substances 0.000 description 56
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 54
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 46
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 45
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 40
- 239000002904 solvent Substances 0.000 description 37
- 238000006880 cross-coupling reaction Methods 0.000 description 30
- 239000003921 oil Substances 0.000 description 29
- 235000019198 oils Nutrition 0.000 description 29
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 28
- 238000009833 condensation Methods 0.000 description 28
- 230000005494 condensation Effects 0.000 description 28
- 238000003786 synthesis reaction Methods 0.000 description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 24
- 230000005764 inhibitory process Effects 0.000 description 24
- 230000015572 biosynthetic process Effects 0.000 description 23
- 238000004587 chromatography analysis Methods 0.000 description 23
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 23
- 239000012044 organic layer Substances 0.000 description 22
- 239000011541 reaction mixture Substances 0.000 description 22
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 230000000694 effects Effects 0.000 description 21
- 239000003480 eluent Substances 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 19
- 230000002829 reductive effect Effects 0.000 description 19
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 17
- 238000010626 work up procedure Methods 0.000 description 17
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 16
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 15
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 15
- 150000001448 anilines Chemical class 0.000 description 15
- 239000006260 foam Substances 0.000 description 15
- 239000004615 ingredient Substances 0.000 description 14
- 239000010410 layer Substances 0.000 description 14
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 12
- 229910052938 sodium sulfate Inorganic materials 0.000 description 12
- 235000011152 sodium sulphate Nutrition 0.000 description 12
- NJXYBTMCTZAUEE-UHFFFAOYSA-N (5-chloropyridin-3-yl)boronic acid Chemical compound OB(O)C1=CN=CC(Cl)=C1 NJXYBTMCTZAUEE-UHFFFAOYSA-N 0.000 description 11
- HRLVPHGCEGTVLK-UHFFFAOYSA-N 5-cyanopyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(C#N)C=N1 HRLVPHGCEGTVLK-UHFFFAOYSA-N 0.000 description 11
- 101150098097 CLTRN gene Proteins 0.000 description 11
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 125000005843 halogen group Chemical group 0.000 description 10
- GJLOKYIYZIOIPN-UHFFFAOYSA-N 5-chloropyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(Cl)C=N1 GJLOKYIYZIOIPN-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 150000001408 amides Chemical class 0.000 description 9
- 239000003054 catalyst Substances 0.000 description 9
- 239000007903 gelatin capsule Substances 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- 229910000029 sodium carbonate Inorganic materials 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 239000000969 carrier Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 125000001010 sulfinic acid amide group Chemical group 0.000 description 8
- JBWYRBLDOOOJEU-UHFFFAOYSA-N 1-[chloro-(4-methoxyphenyl)-phenylmethyl]-4-methoxybenzene Chemical compound C1=CC(OC)=CC=C1C(Cl)(C=1C=CC(OC)=CC=1)C1=CC=CC=C1 JBWYRBLDOOOJEU-UHFFFAOYSA-N 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 125000003277 amino group Chemical group 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000377 silicon dioxide Substances 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 239000000829 suppository Substances 0.000 description 7
- 125000002103 4,4'-dimethoxytriphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)(C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 6
- BMTZEAOGFDXDAD-UHFFFAOYSA-M 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholin-4-ium;chloride Chemical compound [Cl-].COC1=NC(OC)=NC([N+]2(C)CCOCC2)=N1 BMTZEAOGFDXDAD-UHFFFAOYSA-M 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 150000001414 amino alcohols Chemical class 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000012228 culture supernatant Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000825 pharmaceutical preparation Substances 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- DKYRKAIKWFHQHM-UHFFFAOYSA-N (3,5-dichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=CC(Cl)=C1 DKYRKAIKWFHQHM-UHFFFAOYSA-N 0.000 description 5
- 102100033635 Collectrin Human genes 0.000 description 5
- 101000945075 Homo sapiens Collectrin Proteins 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 125000005219 aminonitrile group Chemical group 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
- 125000001309 chloro group Chemical group Cl* 0.000 description 5
- 239000013058 crude material Substances 0.000 description 5
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 5
- SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 description 5
- 125000006413 ring segment Chemical group 0.000 description 5
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 4
- XDBHWPLGGBLUHH-UHFFFAOYSA-N (3-cyanophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(C#N)=C1 XDBHWPLGGBLUHH-UHFFFAOYSA-N 0.000 description 4
- OBOHMJWDFPBPKD-UHFFFAOYSA-N 1-[chloro(diphenyl)methyl]-4-methoxybenzene Chemical compound C1=CC(OC)=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 OBOHMJWDFPBPKD-UHFFFAOYSA-N 0.000 description 4
- CESUXLKAADQNTB-SSDOTTSWSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@](N)=O CESUXLKAADQNTB-SSDOTTSWSA-N 0.000 description 4
- BHZRZUBHFOODOU-UHFFFAOYSA-N 2h-oxazin-3-amine Chemical compound NC1=CC=CON1 BHZRZUBHFOODOU-UHFFFAOYSA-N 0.000 description 4
- RJNUXEDAPIKMDE-UHFFFAOYSA-M 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholin-4-ium;chloride;hydrate Chemical compound O.[Cl-].COC1=NC(OC)=NC([N+]2(C)CCOCC2)=N1 RJNUXEDAPIKMDE-UHFFFAOYSA-M 0.000 description 4
- ZPJLEKVEBRLIAW-UHFFFAOYSA-N 7-bromo-4,4-difluoro-2,3-dihydronaphthalen-1-one Chemical compound BrC1=CC=C2C(F)(F)CCC(=O)C2=C1 ZPJLEKVEBRLIAW-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 4
- 239000012448 Lithium borohydride Substances 0.000 description 4
- 238000006680 Reformatsky reaction Methods 0.000 description 4
- 150000001499 aryl bromides Chemical class 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 125000001246 bromo group Chemical group Br* 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 150000004985 diamines Chemical class 0.000 description 4
- SACNIGZYDTUHKB-UHFFFAOYSA-N ditert-butyl-[2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane Chemical group CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C(C)(C)C)C(C)(C)C SACNIGZYDTUHKB-UHFFFAOYSA-N 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- XGZNHFPFJRZBBT-UHFFFAOYSA-N ethanol;titanium Chemical compound [Ti].CCO.CCO.CCO.CCO XGZNHFPFJRZBBT-UHFFFAOYSA-N 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000003914 insulin secretion Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- HZFPPBMKGYINDF-UHFFFAOYSA-N pyrimidin-5-ylboronic acid Chemical compound OB(O)C1=CN=CN=C1 HZFPPBMKGYINDF-UHFFFAOYSA-N 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- JMXKSZRRTHPKDL-UHFFFAOYSA-N titanium(IV) ethoxide Substances [Ti+4].CC[O-].CC[O-].CC[O-].CC[O-] JMXKSZRRTHPKDL-UHFFFAOYSA-N 0.000 description 4
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- CYEXXDYQJPRMIQ-UHFFFAOYSA-N (5-cyanopyridin-3-yl)boronic acid Chemical compound OB(O)C1=CN=CC(C#N)=C1 CYEXXDYQJPRMIQ-UHFFFAOYSA-N 0.000 description 3
- KYONRVHCWMKWRK-SNVBAGLBSA-N 2-[(1r)-1-amino-6-bromo-2,3-dihydroinden-1-yl]-2,2-difluoroethanol Chemical compound C1=C(Br)C=C2[C@@](N)(C(F)(F)CO)CCC2=C1 KYONRVHCWMKWRK-SNVBAGLBSA-N 0.000 description 3
- CLSYWFXMLCQWAG-UHFFFAOYSA-N 3-nitro-2h-oxazine Chemical compound [O-][N+](=O)C1=CC=CON1 CLSYWFXMLCQWAG-UHFFFAOYSA-N 0.000 description 3
- JTKFIIQGMVKDNZ-UHFFFAOYSA-N 5-fluoropyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(F)C=N1 JTKFIIQGMVKDNZ-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- 101710150192 Beta-secretase 1 Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 0 CC(C)(C)[S@@](*[C@@]1(C(*)(*)C*=C)c(cc(cc2)Br)c2OCC1)=O Chemical compound CC(C)(C)[S@@](*[C@@]1(C(*)(*)C*=C)c(cc(cc2)Br)c2OCC1)=O 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 238000006161 Suzuki-Miyaura coupling reaction Methods 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 208000015756 familial Alzheimer disease Diseases 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 238000010651 palladium-catalyzed cross coupling reaction Methods 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229960005235 piperonyl butoxide Drugs 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 239000003586 protic polar solvent Substances 0.000 description 3
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- UKSZBOKPHAQOMP-SVLSSHOZSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 UKSZBOKPHAQOMP-SVLSSHOZSA-N 0.000 description 2
- YJXVRJHUVACOAO-RDPWEWGOSA-N (ne)-2-methyl-n-(6-nitro-2,3-dihydrochromen-4-ylidene)propane-2-sulfinamide Chemical compound C1=C([N+]([O-])=O)C=C2C(=N/[S@](=O)C(C)(C)C)/CCOC2=C1 YJXVRJHUVACOAO-RDPWEWGOSA-N 0.000 description 2
- NMAYBXVCSPYQJU-JJPCXOLLSA-N (ne)-2-methyl-n-(6-nitro-2-phenyl-2,3-dihydrochromen-4-ylidene)propane-2-sulfinamide Chemical compound O1C2=CC=C([N+]([O-])=O)C=C2C(=N/[S@](=O)C(C)(C)C)/CC1C1=CC=CC=C1 NMAYBXVCSPYQJU-JJPCXOLLSA-N 0.000 description 2
- YRAGYOLVKVWILA-CNCHJIQNSA-N (ne)-n-(2,2-dimethyl-6-nitro-3h-chromen-4-ylidene)-2-methylpropane-2-sulfinamide Chemical compound C1=C([N+]([O-])=O)C=C2C(=N/[S@](=O)C(C)(C)C)/CC(C)(C)OC2=C1 YRAGYOLVKVWILA-CNCHJIQNSA-N 0.000 description 2
- JZPYYWMOVYEOBB-KEWOFRHOSA-N (ne)-n-(6-bromo-2,2-dimethyl-3h-chromen-4-ylidene)-2-methylpropane-2-sulfinamide Chemical compound C1=C(Br)C=C2C(=N/[S@](=O)C(C)(C)C)/CC(C)(C)OC2=C1 JZPYYWMOVYEOBB-KEWOFRHOSA-N 0.000 description 2
- MCFBUBMEOWEMHS-HAZIXKIPSA-N (ne)-n-(6-bromo-2,3-dihydrochromen-4-ylidene)-2-methylpropane-2-sulfinamide Chemical compound C1=C(Br)C=C2C(=N/[S@](=O)C(C)(C)C)/CCOC2=C1 MCFBUBMEOWEMHS-HAZIXKIPSA-N 0.000 description 2
- POKCKDZLDKFZSS-HAZIXKIPSA-N (ne)-n-(6-bromo-2,3-dihydrothiochromen-4-ylidene)-2-methylpropane-2-sulfinamide Chemical compound C1=C(Br)C=C2C(=N/[S@](=O)C(C)(C)C)/CCSC2=C1 POKCKDZLDKFZSS-HAZIXKIPSA-N 0.000 description 2
- MBLZQUPXXZRLDC-UMEWXORHSA-N (ne)-n-(6-bromo-2-phenyl-2,3-dihydrochromen-4-ylidene)-2-methylpropane-2-sulfinamide Chemical compound O1C2=CC=C(Br)C=C2C(=N/[S@](=O)C(C)(C)C)/CC1C1=CC=CC=C1 MBLZQUPXXZRLDC-UMEWXORHSA-N 0.000 description 2
- JFIQOJPCUVCJLX-YRCIUEIISA-N (ne)-n-(6-bromospiro[3h-chromene-2,3'-oxane]-4-ylidene)-2-methylpropane-2-sulfinamide Chemical compound O1C2=CC=C(Br)C=C2C(=N/[S@](=O)C(C)(C)C)/CC21CCCOC2 JFIQOJPCUVCJLX-YRCIUEIISA-N 0.000 description 2
- WXLCDTBTIVJDCE-UHFFFAOYSA-N 1,4-oxazepine Chemical compound O1C=CC=NC=C1 WXLCDTBTIVJDCE-UHFFFAOYSA-N 0.000 description 2
- OBFCMKPFILBCSQ-UHFFFAOYSA-N 1-[chloro-bis(4-methoxyphenyl)methyl]-4-methoxybenzene Chemical compound C1=CC(OC)=CC=C1C(Cl)(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 OBFCMKPFILBCSQ-UHFFFAOYSA-N 0.000 description 2
- ZWGPBBORPZPQNH-SNVBAGLBSA-N 2-[(1r)-1-amino-6-nitro-2,3-dihydroinden-1-yl]-2,2-difluoroethanol Chemical compound C1=C([N+]([O-])=O)C=C2[C@@](N)(C(F)(F)CO)CCC2=C1 ZWGPBBORPZPQNH-SNVBAGLBSA-N 0.000 description 2
- ZAWZXFSNSCRDOJ-ZIAGYGMSSA-N 2-[(2r,4r)-4-amino-6-bromospiro[3h-chromene-2,3'-oxane]-4-yl]-2,2-difluoroethanol Chemical compound C([C@](C1=CC(Br)=CC=C1O1)(N)C(F)(F)CO)[C@]21CCCOC2 ZAWZXFSNSCRDOJ-ZIAGYGMSSA-N 0.000 description 2
- ZAWZXFSNSCRDOJ-UONOGXRCSA-N 2-[(2s,4r)-4-amino-6-bromospiro[3h-chromene-2,3'-oxane]-4-yl]-2,2-difluoroethanol Chemical compound C([C@](C1=CC(Br)=CC=C1O1)(N)C(F)(F)CO)[C@@]21CCCOC2 ZAWZXFSNSCRDOJ-UONOGXRCSA-N 0.000 description 2
- XJPVKKHCNLIQFK-GFCCVEGCSA-N 2-[(4r)-4-amino-2,2-dimethyl-6-nitro-3h-chromen-4-yl]-2,2-difluoroethanol Chemical compound [O-][N+](=O)C1=CC=C2OC(C)(C)C[C@](N)(C(F)(F)CO)C2=C1 XJPVKKHCNLIQFK-GFCCVEGCSA-N 0.000 description 2
- KWOOHRDCZZTZQS-GFCCVEGCSA-N 2-[(4r)-4-amino-6-bromo-2,2-dimethyl-3h-chromen-4-yl]-2,2-difluoroethanol Chemical compound BrC1=CC=C2OC(C)(C)C[C@](N)(C(F)(F)CO)C2=C1 KWOOHRDCZZTZQS-GFCCVEGCSA-N 0.000 description 2
- KDFOTEKIXNXQEW-SNVBAGLBSA-N 2-[(4r)-4-amino-6-bromo-2,3-dihydrothiochromen-4-yl]-2,2-difluoroethanol Chemical compound C1=C(Br)C=C2[C@@](N)(C(F)(F)CO)CCSC2=C1 KDFOTEKIXNXQEW-SNVBAGLBSA-N 0.000 description 2
- LVJOKGQVEAFUFL-OEMAIJDKSA-N 2-[(4r)-4-amino-6-bromo-2-phenyl-2,3-dihydrochromen-4-yl]-2,2-difluoroethanol Chemical compound C([C@](C1=CC(Br)=CC=C1O1)(N)C(F)(F)CO)C1C1=CC=CC=C1 LVJOKGQVEAFUFL-OEMAIJDKSA-N 0.000 description 2
- YEXFIDILSDKNMC-SNVBAGLBSA-N 2-[(4r)-4-amino-6-nitro-2,3-dihydrochromen-4-yl]-2,2-difluoroethanol Chemical compound C1=C([N+]([O-])=O)C=C2[C@@](N)(C(F)(F)CO)CCOC2=C1 YEXFIDILSDKNMC-SNVBAGLBSA-N 0.000 description 2
- GFBKKMRTHXNJMK-OEMAIJDKSA-N 2-[(4r)-4-amino-6-nitro-2-phenyl-2,3-dihydrochromen-4-yl]-2,2-difluoroethanol Chemical compound C([C@](C1=CC(=CC=C1O1)[N+]([O-])=O)(N)C(F)(F)CO)C1C1=CC=CC=C1 GFBKKMRTHXNJMK-OEMAIJDKSA-N 0.000 description 2
- ZEZZCQFQTBAQSH-GFCCVEGCSA-N 2-[2-[(4r)-4-amino-6-bromo-2,3-dihydrochromen-4-yl]-2,2-difluoroethoxy]acetonitrile Chemical compound C1=C(Br)C=C2[C@@](N)(C(F)(F)COCC#N)CCOC2=C1 ZEZZCQFQTBAQSH-GFCCVEGCSA-N 0.000 description 2
- OICVPZKAZXOFAV-QRWMCTBCSA-N 2-[2-[(4r)-4-amino-6-bromo-2-phenyl-2,3-dihydrochromen-4-yl]-2,2-difluoroethoxy]acetonitrile Chemical compound C([C@](C1=CC(Br)=CC=C1O1)(N)C(F)(F)COCC#N)C1C1=CC=CC=C1 OICVPZKAZXOFAV-QRWMCTBCSA-N 0.000 description 2
- GSVDEEUWIHIDEM-GFCCVEGCSA-N 2-[2-[(4r)-4-amino-6-nitro-2,3-dihydrochromen-4-yl]-2,2-difluoroethoxy]acetonitrile Chemical compound C1=C([N+]([O-])=O)C=C2[C@@](N)(C(F)(F)COCC#N)CCOC2=C1 GSVDEEUWIHIDEM-GFCCVEGCSA-N 0.000 description 2
- OBKPLCHMSWQQHF-QRWMCTBCSA-N 2-[2-[(4r)-4-amino-6-nitro-2-phenyl-2,3-dihydrochromen-4-yl]-2,2-difluoroethoxy]acetonitrile Chemical compound C([C@](C1=CC(=CC=C1O1)[N+]([O-])=O)(N)C(F)(F)COCC#N)C1C1=CC=CC=C1 OBKPLCHMSWQQHF-QRWMCTBCSA-N 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- NJHGVAYLDHROPT-UHFFFAOYSA-N 5-(trifluoromethyl)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(C(F)(F)F)C=N1 NJHGVAYLDHROPT-UHFFFAOYSA-N 0.000 description 2
- KMLKUNVLSWKFLA-UHFFFAOYSA-N 6-bromo-2,2-dimethyl-3h-chromen-4-one Chemical compound BrC1=CC=C2OC(C)(C)CC(=O)C2=C1 KMLKUNVLSWKFLA-UHFFFAOYSA-N 0.000 description 2
- PFLPVOXSUCCZDH-UHFFFAOYSA-N 6-bromo-2,3-dihydrochromen-4-one Chemical compound O1CCC(=O)C2=CC(Br)=CC=C21 PFLPVOXSUCCZDH-UHFFFAOYSA-N 0.000 description 2
- OSDHOOBPMBLALZ-UHFFFAOYSA-N 6-bromo-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1CCCC2=CC(Br)=CC=C21 OSDHOOBPMBLALZ-UHFFFAOYSA-N 0.000 description 2
- XXOIZWTYBCTRNE-UHFFFAOYSA-N 6-bromospiro[3h-chromene-2,3'-oxane]-4-one Chemical compound C1C(=O)C2=CC(Br)=CC=C2OC21CCCOC2 XXOIZWTYBCTRNE-UHFFFAOYSA-N 0.000 description 2
- KUAWMWVXZMQZLD-UHFFFAOYSA-N 6-nitro-2,3-dihydrochromen-4-one Chemical compound O1CCC(=O)C2=CC([N+](=O)[O-])=CC=C21 KUAWMWVXZMQZLD-UHFFFAOYSA-N 0.000 description 2
- MLRACZPAMDFORH-UHFFFAOYSA-N 6-nitro-2,3-dihydroinden-1-one Chemical compound [O-][N+](=O)C1=CC=C2CCC(=O)C2=C1 MLRACZPAMDFORH-UHFFFAOYSA-N 0.000 description 2
- YGVDCGFUUUJCDF-UHFFFAOYSA-N 7-bromo-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1CCC(=O)C2=CC(Br)=CC=C21 YGVDCGFUUUJCDF-UHFFFAOYSA-N 0.000 description 2
- GWAQYWSNCVEJMW-UHFFFAOYSA-N 7-nitro-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1CCC(=O)C2=CC([N+](=O)[O-])=CC=C21 GWAQYWSNCVEJMW-UHFFFAOYSA-N 0.000 description 2
- 238000012815 AlphaLISA Methods 0.000 description 2
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 2
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 2
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 2
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 2
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 2
- 108010017640 Aspartic Acid Proteases Proteins 0.000 description 2
- 102000004580 Aspartic Acid Proteases Human genes 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 101000983970 Conus catus Alpha-conotoxin CIB Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 201000010374 Down Syndrome Diseases 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 101100377706 Escherichia phage T5 A2.2 gene Proteins 0.000 description 2
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 2
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 102100040243 Microtubule-associated protein tau Human genes 0.000 description 2
- 101710115937 Microtubule-associated protein tau Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 206010044688 Trisomy 21 Diseases 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 150000004703 alkoxides Chemical class 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- KDPAWGWELVVRCH-UHFFFAOYSA-M bromoacetate Chemical compound [O-]C(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-M 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- LNAMMBFJMYMQTO-FNEBRGMMSA-N chloroform;(1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].ClC(Cl)Cl.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 LNAMMBFJMYMQTO-FNEBRGMMSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- JZBWUTVDIDNCMW-UHFFFAOYSA-L dipotassium;oxido sulfate Chemical compound [K+].[K+].[O-]OS([O-])(=O)=O JZBWUTVDIDNCMW-UHFFFAOYSA-L 0.000 description 2
- 229960003722 doxycycline Drugs 0.000 description 2
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- AAVKMMOZDOGMOP-CHAGWJKLSA-N ethyl 2-[(1r)-1-[[(r)-tert-butylsulfinyl]amino]-6-nitro-2,3-dihydroinden-1-yl]-2,2-difluoroacetate Chemical compound C1=C([N+]([O-])=O)C=C2[C@](C(F)(F)C(=O)OCC)(N[S@](=O)C(C)(C)C)CCC2=C1 AAVKMMOZDOGMOP-CHAGWJKLSA-N 0.000 description 2
- CJIBDGOJGPUKOS-PUAOIOHZSA-N ethyl 2-[(1r)-6-bromo-1-[[(r)-tert-butylsulfinyl]amino]-2,3-dihydroinden-1-yl]-2,2-difluoroacetate Chemical compound C1=C(Br)C=C2[C@](C(F)(F)C(=O)OCC)(N[S@](=O)C(C)(C)C)CCC2=C1 CJIBDGOJGPUKOS-PUAOIOHZSA-N 0.000 description 2
- MNSBIFCQRKPKHK-VPTFNQTCSA-N ethyl 2-[(4r)-4-[[(r)-tert-butylsulfinyl]amino]-2,2-dimethyl-6-nitro-3h-chromen-4-yl]-2,2-difluoroacetate Chemical compound C1=C([N+]([O-])=O)C=C2[C@](C(F)(F)C(=O)OCC)(N[S@](=O)C(C)(C)C)CC(C)(C)OC2=C1 MNSBIFCQRKPKHK-VPTFNQTCSA-N 0.000 description 2
- JOJHQPOXUACPRU-WVDZOPJMSA-N ethyl 2-[(4r)-4-[[(r)-tert-butylsulfinyl]amino]-6-nitro-2,3-dihydrochromen-4-yl]-2,2-difluoroacetate Chemical compound C1=C([N+]([O-])=O)C=C2[C@](C(F)(F)C(=O)OCC)(N[S@](=O)C(C)(C)C)CCOC2=C1 JOJHQPOXUACPRU-WVDZOPJMSA-N 0.000 description 2
- ZYPRATJXKUIYCR-IMBADDJUSA-N ethyl 2-[(4r)-4-[[(r)-tert-butylsulfinyl]amino]-6-nitro-2-phenyl-2,3-dihydrochromen-4-yl]-2,2-difluoroacetate Chemical compound C([C@@](C1=CC(=CC=C1O1)[N+]([O-])=O)(C(F)(F)C(=O)OCC)N[S@](=O)C(C)(C)C)C1C1=CC=CC=C1 ZYPRATJXKUIYCR-IMBADDJUSA-N 0.000 description 2
- RSZOOQIORGVEST-KWMCUTETSA-N ethyl 2-[(4r)-6-bromo-4-[[(r)-tert-butylsulfinyl]amino]-2,2-dimethyl-3h-chromen-4-yl]-2,2-difluoroacetate Chemical compound C1=C(Br)C=C2[C@](C(F)(F)C(=O)OCC)(N[S@](=O)C(C)(C)C)CC(C)(C)OC2=C1 RSZOOQIORGVEST-KWMCUTETSA-N 0.000 description 2
- JXCYZACOIHNUQJ-AKJBCIBTSA-N ethyl 2-[(4r)-6-bromo-4-[[(r)-tert-butylsulfinyl]amino]-2,3-dihydrochromen-4-yl]-2,2-difluoroacetate Chemical compound C1=C(Br)C=C2[C@](C(F)(F)C(=O)OCC)(N[S@](=O)C(C)(C)C)CCOC2=C1 JXCYZACOIHNUQJ-AKJBCIBTSA-N 0.000 description 2
- SGJUVBBTBWMLKJ-AKJBCIBTSA-N ethyl 2-[(4r)-6-bromo-4-[[(r)-tert-butylsulfinyl]amino]-2,3-dihydrothiochromen-4-yl]-2,2-difluoroacetate Chemical compound C1=C(Br)C=C2[C@](C(F)(F)C(=O)OCC)(N[S@](=O)C(C)(C)C)CCSC2=C1 SGJUVBBTBWMLKJ-AKJBCIBTSA-N 0.000 description 2
- SLFPBYIMEZGZTL-FBORMFIOSA-N ethyl 2-[(4r)-6-bromo-4-[[(r)-tert-butylsulfinyl]amino]-2-phenyl-2,3-dihydrochromen-4-yl]-2,2-difluoroacetate Chemical compound C([C@@](C1=CC(Br)=CC=C1O1)(C(F)(F)C(=O)OCC)N[S@](=O)C(C)(C)C)C1C1=CC=CC=C1 SLFPBYIMEZGZTL-FBORMFIOSA-N 0.000 description 2
- IRSJDVYTJUCXRV-UHFFFAOYSA-N ethyl 2-bromo-2,2-difluoroacetate Chemical compound CCOC(=O)C(F)(F)Br IRSJDVYTJUCXRV-UHFFFAOYSA-N 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000005580 one pot reaction Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 2
- VFWRGKJLLYDFBY-UHFFFAOYSA-N silver;hydrate Chemical compound O.[Ag].[Ag] VFWRGKJLLYDFBY-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical group CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- CEDNQBKTINHWBF-VGAJERRHSA-N (4r)-5',5'-difluoro-2-phenyl-6-pyrimidin-5-ylspiro[2,3-dihydrochromene-4,4'-6h-1,3-oxazine]-2'-amine Chemical compound FC1(F)COC(N)=N[C@]11C2=CC(C=3C=NC=NC=3)=CC=C2OC(C=2C=CC=CC=2)C1 CEDNQBKTINHWBF-VGAJERRHSA-N 0.000 description 1
- XANTURTUVGVWMW-QGZVFWFLSA-N (4r)-6-(3,5-dichlorophenyl)-5',5'-difluorospiro[2,3-dihydrochromene-4,4'-6h-1,3-oxazine]-2'-amine Chemical compound FC1(F)COC(N)=N[C@]11C2=CC(C=3C=C(Cl)C=C(Cl)C=3)=CC=C2OCC1 XANTURTUVGVWMW-QGZVFWFLSA-N 0.000 description 1
- FVEDGBRHTGXPOK-UHFFFAOYSA-N (5-fluoropyridin-3-yl)boronic acid Chemical compound OB(O)C1=CN=CC(F)=C1 FVEDGBRHTGXPOK-UHFFFAOYSA-N 0.000 description 1
- ISDFOFZTZUILPE-UHFFFAOYSA-N (5-methoxypyridin-3-yl)boronic acid Chemical compound COC1=CN=CC(B(O)O)=C1 ISDFOFZTZUILPE-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 description 1
- SKWGQIKSBYQUAP-UHFFFAOYSA-N 2,2-dimethyl-6-nitro-3h-chromen-4-one Chemical compound [O-][N+](=O)C1=CC=C2OC(C)(C)CC(=O)C2=C1 SKWGQIKSBYQUAP-UHFFFAOYSA-N 0.000 description 1
- OHIIZICHYGTPJR-SNVBAGLBSA-N 2-[(4r)-4-amino-6-bromo-2,3-dihydrochromen-4-yl]-2,2-difluoroethanol Chemical compound C1=C(Br)C=C2[C@@](N)(C(F)(F)CO)CCOC2=C1 OHIIZICHYGTPJR-SNVBAGLBSA-N 0.000 description 1
- REXUYBKPWIPONM-UHFFFAOYSA-N 2-bromoacetonitrile Chemical compound BrCC#N REXUYBKPWIPONM-UHFFFAOYSA-N 0.000 description 1
- XWQYYPXXESGGEP-UHFFFAOYSA-N 2-nitro-1,4-oxazepine Chemical class [O-][N+](=O)C1=CN=CC=CO1 XWQYYPXXESGGEP-UHFFFAOYSA-N 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- KOVWIHLDVUKCFY-UHFFFAOYSA-N 4,4-dimethyl-7-nitro-2,3-dihydronaphthalen-1-one Chemical compound [O-][N+](=O)C1=CC=C2C(C)(C)CCC(=O)C2=C1 KOVWIHLDVUKCFY-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- ZOLUACWHRMUETA-UHFFFAOYSA-N 4-chloro-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Cl ZOLUACWHRMUETA-UHFFFAOYSA-N 0.000 description 1
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 1
- SEQHEDQNODAFIU-UHFFFAOYSA-N 6-bromo-2,3-dihydroinden-1-one Chemical compound BrC1=CC=C2CCC(=O)C2=C1 SEQHEDQNODAFIU-UHFFFAOYSA-N 0.000 description 1
- SBNPYDJTVGRDAA-UHFFFAOYSA-N 6-bromo-2,3-dihydrothiochromen-4-one Chemical compound S1CCC(=O)C2=CC(Br)=CC=C21 SBNPYDJTVGRDAA-UHFFFAOYSA-N 0.000 description 1
- XTTJSFMIDKNCOE-UHFFFAOYSA-N 6-bromo-2-phenyl-2,3-dihydrochromen-4-one Chemical compound C1C(=O)C2=CC(Br)=CC=C2OC1C1=CC=CC=C1 XTTJSFMIDKNCOE-UHFFFAOYSA-N 0.000 description 1
- VXWNSXFFGQGCAM-UHFFFAOYSA-N 6-nitro-2-phenyl-2,3-dihydrochromen-4-one Chemical compound C1C(=O)C2=CC([N+](=O)[O-])=CC=C2OC1C1=CC=CC=C1 VXWNSXFFGQGCAM-UHFFFAOYSA-N 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102000014303 Amyloid beta-Protein Precursor Human genes 0.000 description 1
- 108010079054 Amyloid beta-Protein Precursor Proteins 0.000 description 1
- 101150058765 BACE1 gene Proteins 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 101710150190 Beta-secretase 2 Proteins 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 238000006443 Buchwald-Hartwig cross coupling reaction Methods 0.000 description 1
- MCFBUBMEOWEMHS-OTMARIDSSA-N CC(C)(C)[S@@](/N=C1/c2cc(Br)ccc2OCC1)=O Chemical compound CC(C)(C)[S@@](/N=C1/c2cc(Br)ccc2OCC1)=O MCFBUBMEOWEMHS-OTMARIDSSA-N 0.000 description 1
- SAZPJVBSZHRBSF-CYBMUJFWSA-N CCC(c(c([C@@]1(C#C)N=C(N)OCC1(F)F)c1)ccc1Br)(F)F Chemical compound CCC(c(c([C@@]1(C#C)N=C(N)OCC1(F)F)c1)ccc1Br)(F)F SAZPJVBSZHRBSF-CYBMUJFWSA-N 0.000 description 1
- FLXQETFKGWGVJV-JHLYMETGSA-N CCOCC([C@@](C1)(c(cc(cc2)Br)c2OC11COCCC1)N[S@](B=C)=O)(F)F Chemical compound CCOCC([C@@](C1)(c(cc(cc2)Br)c2OC11COCCC1)N[S@](B=C)=O)(F)F FLXQETFKGWGVJV-JHLYMETGSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 101710138990 Collectrin Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 102000006754 Hepatocyte Nuclear Factor 1 Human genes 0.000 description 1
- 108010086512 Hepatocyte Nuclear Factor 1 Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100268553 Homo sapiens APP gene Proteins 0.000 description 1
- 101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 description 1
- 101000617536 Homo sapiens Presenilin-1 Proteins 0.000 description 1
- 101000617546 Homo sapiens Presenilin-2 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- QCFBUVJBLWCNHF-CYBMUJFWSA-N NC(OCC1(F)F)=N[C@@]1(c1c2)C#CCCc1ccc2Br Chemical compound NC(OCC1(F)F)=N[C@@]1(c1c2)C#CCCc1ccc2Br QCFBUVJBLWCNHF-CYBMUJFWSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 101100352419 Pithecopus hypochondrialis psn1 gene Proteins 0.000 description 1
- 101100352425 Pithecopus hypochondrialis psn2 gene Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102100022033 Presenilin-1 Human genes 0.000 description 1
- 102100022036 Presenilin-2 Human genes 0.000 description 1
- 108010050254 Presenilins Proteins 0.000 description 1
- 102000015499 Presenilins Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- LCKIEQZJEYYRIY-UHFFFAOYSA-N Titanium ion Chemical compound [Ti+4] LCKIEQZJEYYRIY-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000007792 alzheimer disease pathology Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005050 dihydrooxazolyl group Chemical group O1C(NC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000004970 emotional disturbance Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- YWQCKBMOFTVGNW-HZAQMHFWSA-N ethyl 2-[(1r)-1-[[(r)-tert-butylsulfinyl]amino]-4,4-dimethyl-7-nitro-2,3-dihydronaphthalen-1-yl]-2,2-difluoroacetate Chemical compound C1=C([N+]([O-])=O)C=C2[C@](C(F)(F)C(=O)OCC)(N[S@](=O)C(C)(C)C)CCC(C)(C)C2=C1 YWQCKBMOFTVGNW-HZAQMHFWSA-N 0.000 description 1
- KPFRHPGRLFVYIU-JYRCXFKTSA-N ethyl 2-[(1r)-1-[[(r)-tert-butylsulfinyl]amino]-7-nitro-3,4-dihydro-2h-naphthalen-1-yl]-2,2-difluoroacetate Chemical compound C1=C([N+]([O-])=O)C=C2[C@](C(F)(F)C(=O)OCC)(N[S@](=O)C(C)(C)C)CCCC2=C1 KPFRHPGRLFVYIU-JYRCXFKTSA-N 0.000 description 1
- BIBDYDVOSNZVOH-WGDIFIGCSA-N ethyl 2-[(1r)-7-bromo-1-[[(r)-tert-butylsulfinyl]amino]-3,4-dihydro-2h-naphthalen-1-yl]-2,2-difluoroacetate Chemical compound C1=C(Br)C=C2[C@](C(F)(F)C(=O)OCC)(N[S@](=O)C(C)(C)C)CCCC2=C1 BIBDYDVOSNZVOH-WGDIFIGCSA-N 0.000 description 1
- RUKAJUNVWBXLSY-WVDZOPJMSA-N ethyl 2-[(1r)-7-bromo-1-[[(r)-tert-butylsulfinyl]amino]-4,4-difluoro-2,3-dihydronaphthalen-1-yl]-2,2-difluoroacetate Chemical compound C1=C(Br)C=C2[C@](C(F)(F)C(=O)OCC)(N[S@](=O)C(C)(C)C)CCC(F)(F)C2=C1 RUKAJUNVWBXLSY-WVDZOPJMSA-N 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000005454 flavour additive Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 235000019680 high-energy food Nutrition 0.000 description 1
- 102000046783 human APP Human genes 0.000 description 1
- 102000050078 human CLTRN Human genes 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- YLYIPIXERYDHQI-AOARFAJZSA-N n-[(4r)-4-(1,1-difluoro-2-hydroxyethyl)-6-nitro-2-phenyl-2,3-dihydrochromen-4-yl]-2-methylpropane-2-sulfinamide Chemical compound C([C@](C1=CC(=CC=C1O1)[N+]([O-])=O)(N[S@](=O)C(C)(C)C)C(F)(F)CO)C1C1=CC=CC=C1 YLYIPIXERYDHQI-AOARFAJZSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000005961 oxazepanyl group Chemical group 0.000 description 1
- YRKXMHZOKUGRML-UHFFFAOYSA-N oxazepin-3-amine Chemical class NC1=NOC=CC=C1 YRKXMHZOKUGRML-UHFFFAOYSA-N 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000005412 pyrazyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- GRJJQCWNZGRKAU-UHFFFAOYSA-N pyridin-1-ium;fluoride Chemical compound F.C1=CC=NC=C1 GRJJQCWNZGRKAU-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000005297 thienyloxy group Chemical group S1C(=CC=C1)O* 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- PTIBVSAWRDGWAE-UHFFFAOYSA-K trisodium;phosphate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[O-]P([O-])([O-])=O PTIBVSAWRDGWAE-UHFFFAOYSA-K 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
Definitions
- AD Alzheimer's disease
- Its clinical symptoms are impairment of memory, cognition, temporal and local orientation, judgment and reasoning but also severe emotional disturbances.
- AD has become a major health problem in all societies with high life expectancies and also a significant economic burden for their health systems.
- AD is characterized by 2 major pathologies in the central nervous system (CNS), the occurrence of amyloid plaques and neurofibrillar tangles (Hardy et al., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science. 2002 Jul 19;297(5580):353-6, Selkoe, Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease, Annu Rev Cell Biol. 1994;10:373-403). Both pathologies are also commonly observed in patients with Down's syndrome (trisomy 21), which also develop AD-like symptoms in early life. Neurofibrillar tangles are intracellular aggregates of the microtubule-associated protein tau (MAPT).
- MTT microtubule-associated protein tau
- Amyloid plaques occur in the extracellular space; their principal components are ⁇ -peptides.
- the latter are a group of proteolytic fragments derived from the ⁇ -amyloid precursor protein (APP) by a series of proteolytic cleavage steps.
- APP ⁇ -amyloid precursor protein
- proteolytic cleavage steps Several forms of APP have been identified of which the most abundant are proteins of 695, 751 and 770 amino acids length. They all arise from a single gene through differential splicing.
- the ⁇ -peptides are derived from the same domain of the APP but differ at their N- and C-termini, the main species are of 40 and 42 amino-acid length.
- ⁇ -peptides are the essential molecules in the pathogenesis of AD: 1) amyloid plaques formed of ⁇ -peptides are invariably part of the AD pathology; 2) ⁇ - peptides are toxic for neurons; 3) in Familial Alzheimer's Disease (FAD) the mutations in the disease genes APP, PSN1, PSN2 lead to increased levels of ⁇ -peptides and early brain amyloidosis; 4) transgenic mice which express such FAD genes develop a pathology which bears many resemblances to the human disease.
- ⁇ -peptides are produced from APP through the sequential action of 2 proteolytic enzymes termed ⁇ - and ⁇ -secretase.
- ⁇ -Secretase cleaves first in the extracellular domain of APP approximately 28 amino acids outside of the trans-membrane domain (TM) to produce a C-terminal fragment of APP containing the TM- and the cytoplasmatic domain ( ⁇ ).
- CTF ⁇ is the substrate for ⁇ -secretase which cleaves at several adjacent positions within the TM to produce the ⁇ peptides and the cytoplasmic fragment.
- the ⁇ -secretase is a complex of at least 4 different proteins, its catalytic subunit is very likely a presenilin protein (PSEN1, PSEN2).
- the ⁇ -secretase (BACE1, Asp2; BACE stands for ⁇ -site APP-cleaving enzyme) is an aspartyl protease which is anchored into the membrane by a transmembrane domain (Vassar et al., Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE, Science. 1999 Oct 22;286(5440):735). It is expressed in many tissues of the human organism but its level is especially high in the CNS.
- mice which have been genetically engineered to express the human APP gene and which form extensive amyloid plaques and Alzheimer's disease like pathologies during aging fail to do so when ⁇ -secretase activity is reduced by genetic ablation of one of the BACE1 alleles (McConlogue et al., Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice. J Biol Chem. 2007 Sep 7;282(36):26326). It is thus presumed that inhibitors of BACE1 activity can be useful agents for therapeutic intervention in Alzheimer's disease (AD).
- AD Alzheimer's disease
- Type 2 diabetes is caused by insulin resistance and inadequate insulin secretion from pancreatic ⁇ -cells leading to poor blood-glucose control and hyperglycemia (M Prentki & CJ Nolan, "Islet beta-cell failure in type 2 diabetes.” J. Clin. Investig. 2006, 116(7), 1802-1812).
- Patients with T2D have an increased risk of microvascular and macrovascular disease and a range of related complications including diabetic nephropathy, retinopathy and cardiovascular disease.
- Tmem27 has been identified as a protein promoting beta-cell proliferation (P Akpinar, S Kuwajima, J Kriitzfeldt, M Stoffel, "Tmem27: A cleaved and shed plasma membrane protein that stimulates pancreatic ⁇ cell proliferation", Cell Metab.
- Tmem27 is a 42 kDa membrane glycoprotein which is constitutively shed from the surface of ⁇ -cells, resulting from a degradation of the full-length cellular Tmem27.
- Overexpression of Tmem27 in a transgenic mouse increases ⁇ -cell mass and improves glucose tolerance in a diet-induced obesity DIO model of diabetes.
- siRNA knockout of Tmem27 in a rodent ⁇ -cell proliferation assay reduces the proliferation rate, indicating a role for Tmem27 in control of ⁇ -cell mass.
- BACE2 inhibitors In the same proliferation assay, BACE2 inhibitors also increase proliferation. However, BACE2 inhibition combined with Tmem27 siRNA knockdown results in low proliferation rates. Therefore, it is concluded that BACE2 is the protease responsible for the degradation of Tmem27. Furthermore, in vitro, BACE2 cleaves a peptide based on the sequence of Tmem27. The closely related protease BACEl does not cleave this peptide and selective inhibition of BACEl alone does not enhance proliferation of ⁇ -cells.
- BACE2 The close homolog BACE2 is a membrane-bound aspartyl protease and is co-localized with Tmem27 in human pancreatic ⁇ -cells (G Finzi, F Franzi, C Placidi, F Acquati et al., "BACE2 is stored in secretory granules of mouse and rat pancreatic beta cells", Ultrastruct Pathol. 2008, 32(6), 246-251). It is also known to be capable of degrading APP (I Hussain, D Powell, D Howlett, G Chapman et al., "ASP1 (BACE2) cleaves the amyloid precursor protein at the ⁇ -secretase site" Mol Cell Neurosci.
- IL-1R2 P Kuhn, E Marjaux, A Imhof, B De Strooper et al., "Regulated intramembrane proteolysis of the interleukin-1 receptor II by alpha-, beta-, and gamma-secretase" J. Biol. Chem. 2007, 282(16), 11982-11995) and ACE2.
- the capability to degrade ACE2 indicates a possible role of BACE2 in the control of hypertension.
- BACE2 Inhibition of BACE2 is therefore proposed as a treatment for T2D with the potential to preserve and restore ⁇ -cell mass and stimulate insulin secretion in pre-diabetic and diabetic patients. It is therefore an object of the present invention to provide selective BACE2 inhibitors. Such compounds are useful as therapeutically active substances, particularly in the treatment and/or prevention of diseases which are associated with the inhibition of BACE2.
- ⁇ -amyloid peptides in, on or around neurological tissue are inhibited by the present compounds, i.e. inhibition of the ⁇ -production from APP or an APP fragment.
- the present invention provides novel compounds of formula I, their manufacture, medicaments based on a compound in accordance with the invention and their production as well as the use of compounds of formula I in the control or prevention of illnesses such as Alzheimer's disease and type 2 diabetes.
- the novel compounds of formula I have improved pharmacological properties.
- the present invention provides spiro-[l,3]-oxazines and spiro-[l,4]-oxazepines having BACE1 and/or BACE2 inhibitory properties, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. Summary of the Invention
- the present invention provides a compounds of formula I,
- the present compounds have Asp2 ( ⁇ -secretase, BACE1 or Memapsin-2) inhibitory activity and can therefore be used in the therapeutic and/or prophylactic treatment of diseases and disorders characterized by elevated ⁇ -amyloid levels and/or ⁇ -amyloid oligomers and/or ⁇ -amyloid plaques and further deposits, particularly Alzheimer's disease. And/or the present compounds have BACE2 inhibitory activity and can therefore be used in the therapeutic and/or prophylactic treatment of diseases and disorders such as type 2 diabetes and other metabolic disorders.
- the present invention provides a compound of formula I and their pharmaceutically acceptable salts thereof, the preparation of the above mentioned compounds, medicaments containing them and their manufacture as well as the use of the above mentioned compounds in the therapeutic and/or prophylactic treatment of diseases and disorders which are associated with inhibition of BACE1 and/or BACE2 activity, such as Alzheimer's disease and type 2 diabetes. Furthermore, the formation, or formation and deposition, of ⁇ -amyloid plaques in, on or around neurological tissue (e.g., the brain) are inhibited by the present compounds by inhibiting the ⁇ production from APP or an APP fragment.
- Ci_6-alkyl stands for a hydrocarbon radical which can be linear or branched, with single or multiple branching, wherein the alkyl group in general contains 1 to 6 carbon atoms, for example, methyl (Me), ethyl (Et), propyl, isopropyl (i-propyl), n-butyl, i-butyl (isobutyl), 2-butyl (sec-butyl), t-butyl (tert-butyl), isopentyl, 2-ethyl-propyl, 1 ,2-dimethyl-propyl and the like.
- Ci_3-alkyl stands for a hydrocarbon radical which can be linear or branched, wherein the alkyl group comprises 1 to 3 carbon atoms. Particular examples are “Ci_6-alkyl” are “Ci_3-alkyl”. Specific examples are methyl and ethyl. Most specific group is methyl.
- cyano-Ci-6-alkyl refers to C 1-6 - alkyl as defined herein, which is substituted by one or multiple cyano, particularly 1-5 cyano, more particularly 1 cyano. Examples are cyano-methyl and the like.
- halogen-Ci_6-alkyl alone or in combination with other groups, refers to C 1-6 - alkyl as defined herein, which is substituted by one or multiple halogen, particularly 1-5 halogen, more particularly 1-3 halogen, most particularly 1 halogen or 3 halogen.
- halogen-Ci_3- alkyl refers to Ci_3-alkyl as defined herein, which is substituted by one or multiple halogen, particularly 1-5 halogen, more particularly 1-3 halogen, most particularly 1 halogen or 3 halogen.
- Particular halogen is fluoro.
- Particular "halogen-C h alky! is fluoro-Ci-6-alkyl and particular "halogen-Ci-3-alkyl” is fluoro-Ci-3-alkyl. Examples are difluoromethyl, chloromethyl, fhioromethyl and the like. A specific example is trifluoromefhyl.
- Ci_6-alkoxy-Ci_6-alkyl refers to Ci_ 6-alkyl, which is substituted by one or multiple Ci_6-alkoxy as defined herein. Examples are MeO-Me, lMeO-Et, 2MeO-Et, lMeO-2EtO-propyl and the like.
- cyano alone or in combination with other groups, refers to N ⁇ C-(CN).
- halogen denotes chloro (CI), iodo (I), fluoro (F) and bromo (Br). Particular "halogen” are CI and F. Specific "halogen” is F.
- heteroaryl alone or in combination with other groups, refers to an aromatic carbocyclic group of having a single 4 to 8 membered ring or multiple condensed rings containing 6 to 14, in particular 6 to 10 ring atoms and containing 1, 2 or 3 heteroatoms individually selected from N, O and S, in particular N and O, in which group at least one heterocyclic ring is aromatic.
- heteroaryl examples include benzofuryl, benzoimidazolyl, lH-benzoimidazolyl, benzooxazinyl, benzoxazolyl, benzothiazinyl, benzothiazolyl, benzothienyl, benzotriazolyl, furyl, imidazolyl, indazolyl, lH-indazolyl, indolyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl (pyrazyl), lH-pyrazolyl, pyrazolo[l,5-a]pyridinyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, quinolinyl, tetrazolyl, thiazolyl, thienyl, triazolyl, 6,7-dihydro-5H
- heteroaryl are pyridinyl, pyrimidinyl and lH-pyrazolyl.
- Specific groups are pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-5-yl and lH-pyrazol-5-yl.
- aryl denotes a monovalent aromatic carbocyclic mono- or bicyclic ring system comprising 6 to 10 carbon ring atoms.
- aryl moieties include phenyl and naphthyl. Particular "aryl” is phenyl.
- heterocyclyl denotes a monovalent saturated or partly unsaturated mono- or bicyclic ring system of 4 to 9 ring atoms, containing 1, 2, or 3 ring heteroatoms selected from N, O and S, the remaining ring atoms being carbon.
- Bicyclic means consisting of two cycles having two ring atoms in common, i.e. the bridge separating the two rings is either a single bond or a chain of one or two ring atoms.
- Examples for monocyclic saturated heterocyclyl are azetidinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydro- thienyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperazinyl, morpholinyl, thiomorpholinyl, 1, 1-dioxo- thiomorpholin-4-yl, azepanyl, diazepanyl, homopiperazinyl, or oxazepanyl.
- bicyclic saturated heterocyclyl examples include 8-aza-bicyclo[3.2.1]octyl, quinuclidinyl, 8-oxa-3-aza- bicyclo[3.2.1]octyl, 9-aza-bicyclo[3.3.1]nonyl, 3-oxa-9-aza-bicyclo[3.3.1]nonyl, or 3-thia-9-aza- bicyclo[3.3.1]nonyl.
- partly unsaturated heterocyclyl examples include dihydrofuryl, imidazolinyl, dihydro-oxazolyl, tetrahydro-pyridinyl, or dihydropyranyl. Particular "heterocyclyl” is tetrahydrofuranyl .
- Ci_6-alkoxy alone or in combination with other groups, stands for an
- -O-Ci-6-alkyl radical which can be linear or branched, with single or multiple branching, wherein the alkyl group in general comprises 1 to 6 carbon atoms, for example, methoxy (OMe, MeO), ethoxy (OEt), propoxy, isopropoxy (i-propoxy), n-butoxy, i-butoxy (iso-butoxy), 2-butoxy (sec-butoxy), t-butoxy (tert-butoxy), isopentyloxy (i-pentyloxy) and the like.
- Particular "Ci-6-alkoxy" are groups with 1 to 4 carbon atoms. Specific examples are methoxy and ethoxy.
- halogen-Ci-6-alkoxy alone or in combination with other groups, refers to Ci_6- alkoxy as defined herein, which is substituted by one or multiple halogens, in particular fluoro.
- Particular "halogen-Ci_6-alkoxy” are fluoro-Ci_6-alkoxy.
- Specific groups are difluoromethoxy and trifluoromethoxy.
- C2-6-alkynyl denotes a monovalent linear or branched saturated hydrocarbon group of 2 to 6 carbon atoms, in particular from 2 to 4 carbon atoms, and comprising one, two or three triple bonds.
- Examples of C2-6-alkynyl include ethynyl, propynyl and n-butynyl. Specific examples are ethynyl and propynyl.
- salts refers to salts that are suitable for use in contact with the tissues of humans and animals.
- suitable salts with inorganic and organic acids are, but are not limited to acetic acid, citric acid, formic acid, fumaric acid, hydrochloric acid, lactic acid, maleic acid, malic acid, methane-sulfonic acid, nitric acid, phosphoric acid, p-toluenesulphonic acid, succinic acid, sulfuric acid, sulphuric acid, tartaric acid, trifluoro acetic acid and the like.
- Specific examples are formic acid, trifluoroacetic acid and hydrochloric acid.
- pharmaceutically acceptable carrier and “pharmaceutically acceptable auxiliary substance” refer to carriers and auxiliary substances such as diluents or excipients that are compatible with the other ingredients of the formulation.
- composition encompasses a product comprising specified ingredients in pre-determined amounts or proportions, as well as any product that results, directly or indirectly, from combining specified ingredients in specified amounts. Particularly it encompasses a product comprising one or more active ingredients, and an optional carrier comprising inert ingredients, as well as any product that results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients.
- inhibitor denotes a compound which competes with, reduces or prevents the binding of a particular ligand to particular receptor or which reduces or prevents the inhibition of the function of a particular protein.
- IC 50 half maximal inhibitory concentration
- IC 50 values can be converted logarithmically to pICso values (-log IC 50 ), in which higher values indicate exponentially greater potency.
- the IC 50 value is not an absolute value but depends on experimental conditions e.g. concentrations employed.
- the IC 50 value can be converted to an absolute inhibition constant (Ki) using the Cheng-Prusoff equation (Biochem. Pharmacol. (1973) 22:3099).
- Ki absolute inhibition constant
- Ki values can be converted logarithmically to pKi values (-log Ki), in which higher values indicate exponentially greater potency.
- “Therapeutically effective amount” means an amount of a compound that, when administered to a subject for treating a disease state, is sufficient to effect such treatment for the disease state.
- the “therapeutically effective amount” will vary depending on the compound, disease state being treated, the severity or the disease treated, the age and relative health of the subject, the route and form of administration, the judgment of the attending medical or veterinary practitioner, and other factors.
- variable incorporates by reference the broad definition of the variable as well as preferred, more preferred and most preferred definitions, if any.
- treating when referring to a chemical reaction means adding or mixing two or more reagents under appropriate conditions to produce the indicated and/or the desired product. It should be appreciated that the reaction which produces the indicated and/or the desired product may not necessarily result directly from the combination of two reagents which were initially added, i.e., there can be one or more intermediates which are produced in the mixture which ultimately leads to the formation of the indicated and/or the desired product.
- protecting group denotes the group which selectively blocks a reactive site in a multifunctional compound such that a chemical reaction can be carried out selectively at another unprotected reactive site in the meaning conventionally associated with it in synthetic chemistry.
- Protecting groups can be removed at the appropriate point.
- Exemplary protecting groups are amino-protecting groups, carboxy-protecting groups or hydroxy-protecting groups.
- amino-protecting group denotes groups intended to protect an amino group and includes benzyl, benzyloxycarbonyl (carbobenzyloxy, CBZ), 9-Fluorenylmethyloxycarbonyl (FMOC), p- methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, tert-butoxycarbonyl (BOC), triphenylmethyl (Tr), 4-monomethoxytrityl (MMTr), 4,4-dimefhoxy-trityl (DMTr), 4,4',4"- trimethoxytrityl and trifluoroacetyl. Further examples of these groups are found in T. W. Greene and P. G. M.
- protected amino group refers to an amino group substituted by an amino-protecting groups. Particular amino-protecting groups are tert-butoxycarbonyl group and dimethoxytrityl.
- leaving group denotes the group with the meaning conventionally associated with it in synthetic organic chemistry, i.e., an atom or group displaceable under substitution reaction conditions.
- leaving groups include halogen, in particular bromo, alkane- or arylenesulfonyloxy, such as methanesulfonyloxy, ethanesulfonyloxy, thiomethyl, benzenesulfonyloxy, tosyloxy, and thienyloxy, dihalophosphinoyloxy, optionally substituted benzyloxy, isopropyloxy, and acyloxy.
- aromatic denotes the conventional idea of aromaticity as defined in the literature, in particular in IUPAC - Compendium of Chemical Terminology, 2nd, A. D. McNaught & A. Wilkinson (Eds). Blackwell Scientific Publications, Oxford (1997).
- pharmaceutically acceptable excipient denotes any ingredient having no therapeutic activity and being non-toxic such as disintegrators, binders, fillers, solvents, buffers, tonicity agents, stabilizers, antioxidants, surfactants or lubricants used in formulating pharmaceutical products.
- the invention also provides pharmaceutical compositions, methods of using, and methods of preparing the aforementioned compounds.
- One embodiment of the invention is a compound of formula I,
- V is -CR 7a R 7b -;
- W is -CR ⁇ R 213 -;
- X is -CR la R lb -, -0-, -S - or -S0 2 -;
- z is selected from the £ ;roup consisting of
- aryl substituted by 1-4 substituents individually selected from R 8 is selected from the group consisting of
- R 2a and R 2b together with the C they are attached form a heterocyclyl; is selected from the group consisting of
- a certain embodiment is a compound as described herein, wherein
- V is -CR 7a R 7b -;
- X is -CR la R lb -, -0-, -S- or -S0 2 -;
- z is selected from the group consisting of
- heteroaryl substituted by 1-2 substituents individually selected from R and hi) aryl substituted by 1-2 substituents individually selected from R , is selected from the group consisting of
- R 7b is hydrogen
- R 8 is selected from the group consisting of
- n 0 or 1
- n 0 or 1
- p is 0 or 1; or pharmaceutically acceptable salts thereof.
- a certain embodiment is a compound as described herein, wherein
- V is -CR 7a R 7b -;
- w is -CR ⁇ R 213 -;
- X is -CR la R lb -;
- z is selected from the group consisting of
- R la is selected from the group consisting of
- R lb is selected from the group consisting of
- R a is selected from the group consisting of
- R 2b is selected from the group consisting of
- R 3 is halogen
- R 4 is halogen
- R 5 is hydrogen
- R 7b is hydrogen
- R 8 is selected from the group consisting of
- n 0 or 1
- n 0 or 1
- P is 0 or 1 or pharmaceutically acceptable salts thereof.
- a certain embodiment is a compound as described herein, wherein
- X is -CR la R lb -;
- R la is hydrogen
- R lb is hydrogen
- R 3 is halogen
- R 4 is halogen
- R 5 is hydrogen
- R 6 is hydrogen
- R 7a is hydrogen
- R 7b is hydrogen
- R 8 is selected from the group consisting of
- n 0;
- n 1;
- P is 0; pharmaceutically acceptable salts thereof.
- a certain embodiment is a compound as described herein, wherein n is 0.
- a certain embodiment is a compound as described herein, wherein n is i.
- a certain embodiment is a compound as described herein, wherein m is 0.
- a certain embodiment is a compound as described herein, wherein m is 1.
- a certain embodiment is a compound as described herein, wherein p is 0.
- a certain embodiment is a compound as described herein, wherein, wherein p is 1.
- a certain embodiment is a compound as described herein, wherein X is -CR la R lb - and R la and R lb are both hydrogen.
- a certain embodiment is a compound as described herein, wherein X is -CR la R lb -.
- a certain embodiment is a compound as described herein, wherein R la is hydrogen.
- a certain embodiment is a compound as described herein, wherein R la is halogen.
- a certain embodiment is a compound as described herein, wherein R la is F.
- a certain embodiment is a compound as described herein, wherein R la is Ci_6-alkyl.
- a certain embodiment is a compound as described herein, wherein R la is methyl.
- a certain embodiment is a compound as described herein, wherein R lb is hydrogen.
- a certain embodiment is a compound as described herein, wherein R lb is halogen.
- a certain embodiment is a compound as described herein, wherein R lb is F.
- a certain embodiment is a compound as described herein, wherein R lb is Ci ⁇ -alkyl.
- a certain embodiment is a compound as described herein, wherein R lb is methyl.
- a certain embodiment is a compound as described herein, wherein R 2a is Ci_6-alkyl.
- a certain embodiment is a compound as described herein, wherein R 2a is methyl.
- a certain embodiment is a compound as described herein, wherein R 2a is hydrogen.
- a certain embodiment is a compound as described herein, wherein R 2b is Ci_6-alkyl.
- a certain embodiment is a compound as described herein, wherein R 2b is methyl.
- a certain embodiment is a compound as described herein, wherein R 2b is hydrogen.
- a certain embodiment is a compound as described herein, wherein R 2b is aryl.
- a certain embodiment is a compound as described herein, wherein R 2b is phenyl.
- a certain embodiment is a compound as described herein, wherein R 2a and R 2b form together with the C to which they are attached form heterocyclyl.
- a certain embodiment is a compound as described herein, wherein R a and R form together with the C to which they are attached tetrahydropyranyl.
- a certain embodiment is a compound as described herein, wherein X is -0-.
- a certain embodiment is a compound as described herein, wherein X is -S-.
- a certain embodiment is a compound as described herein, wherein X is -S0 2 -.
- a certain embodiment is a compound as described herein, wherein p is 1, W is -CR 2a R 2b - and R 2a and R 2b are both hydrogen.
- a certain embodiment is a compound as described herein, wherein V is -CR 7a R 7b - and R 7a and R 7b are both hydrogen.
- a certain embodiment is a compound as described herein, wherein V is -CR 7a R 7b -.
- a certain embodiment is a compound as described herein, wherein R 7a is hydrogen.
- a certain embodiment is a compound as described herein, wherein R 7b is hydrogen.
- a certain embodiment is a compound as described herein, wherein W is -CR 2a R 2b -.
- a certain embodiment is a compound as described herein, wherein R 3 is halogen.
- a certain embodiment is a compound as described herein, wherein R 3 is F.
- a certain embodiment is a compound as described herein, wherein R 4 is halogen.
- a certain embodiment is a compound as described herein, wherein R 4 is F.
- a certain embodiment is a compound as described herein, wherein R 5 is hydrogen.
- a certain embodiment is a compound as described herein, wherein R 6 is hydrogen.
- a certain embodiment is a compound as described herein, wherein Z is heteroaryl substituted by halogen or cyano.
- a certain embodiment is a compound as described herein, wherein Z is 2-chloropyridinyl, 3,5-dichlorophenyl, 3,5-dichloropyridinyl, 3-cyano-phenyl, 4-chloro-lH-pyrazoleyl, 5- chloropyridinyl, 5-chloropyridinyl, 5-cyanopyridinyl, 5-cyanopyridinyl, 5-fluoropyridinyl, 5- fluoropyridinyl, 5-methoxypyridinyl, 5-trifluoromethylpyridinyl or pyrimidinyl.
- a certain embodiment is a compound as described herein, wherein Z is 2-chloropyridin-4- yl, 3,5-dichlorophenyl, 3,5-dichloropyridin-2-yl, 3-cyano-phenyl, 4-chloro-lH-pyrazole-5-yl, 5- chloropyridin-2-yl, 5-chloropyridin-3-yl, 5-cyanopyridin-2-yl, 5-cyanopyridin-3-yl, 5- fluoropyridin-2-yl, 5-fluoropyridin-3-yl, 5-methoxypyridin-3-yl, 5-trifluoromethylpyridin-2-yl or pyrimidin-5-yl.
- a certain embodiment is a compound as described herein, wherein Z is 5-cyanopyridin-2- yl, 5-chloropyridin-2-yl, 5-chloropyridin-3-yl or 5-fluoropyridin-2-yl.
- a certain embodiment is a compound as described herein, wherein Z is heteroaryl.
- a certain embodiment is a compound as described herein, wherein Z is pyrimidinyl.
- a certain embodiment is a compound as described herein, wherein Z is heteroaryl substituted by 1-2 substituents individually selected from R 8 .
- a certain embodiment is a compound as described herein, wherein Z is IH-pyrazolyl, pyridinyl or pyrimidinyl.
- a certain embodiment is a compound as described herein, wherein Z is lH-pyrazol-5-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl or pyrimidin-5-yl.
- a certain embodiment is a compound as described herein, wherein Z is aryl.
- a certain embodiment is a compound as described herein, wherein Z is aryl substituted by 1-4 substituents individually selected from R 8 .
- a certain embodiment is a compound as described herein, wherein Z is phenyl substituted by 1-2 substituents individually selected from chloro and cyano.
- a certain embodiment is a compound as described herein, wherein R 8 is cyano.
- a certain embodiment is a compound as described herein, wherein R 8 is halogen.
- a certain embodiment is a compound as described herein, wherein R 8 is chloro.
- a certain embodiment is a compound as described herein, wherein R 8 is fluoro.
- a certain embodiment is a compound as described herein, wherein R 8 is halogen-Ci_6-alkyl.
- a certain embodiment is a compound as described herein, wherein R 8 is trifluoromethyl.
- a certain embodiment is a compound as described herein, wherein R 8 is Ci_6-alkoxy.
- a certain embodiment is a compound as described herein, wherein R 8 is methoxy.
- a certain embodiment is a compound as described herein, selected from the group consisting of
- a certain embodiment is a compound as described herein, selected from the group consisting of (R)-N-(2'-Amino-5',5'-difluoro-2,3,5',6'-tetrahydrospiro[indene-l,4'-[l,3]oxazine]-6-yl)-5- cyanopicolinamide,
- a certain embodiment of the invention provides a process as described below,
- a certain embodiment of the invention provides a compound of formula I as described herein, whenever prepared by a process as defined above.
- a certain embodiment of the invention provides a compound of formula I as described herein for use as therapeutically active substance.
- a certain embodiment of the invention provides a compound of formula I as described herein for the use as inhibitor of BACE1 and/or BACE2 activity.
- a certain embodiment of the invention provides a compound of formula I as described herein for the use as inhibitor of BACE1 activity.
- a certain embodiment of the invention provides a compound of formula I as described herein for the use as inhibitor of BACE2 activity.
- a certain embodiment of the invention provides a compound of formula I as described herein for the use as inhibitor of BACE1 and BACE2 activity.
- a certain embodiment of the invention provides a compound of formula I as described herein for the use as therapeutically active substance for the therapeutic and/or prophylactic treatment of diseases and disorders characterized by elevated ⁇ -amyloid levels and/or ⁇ -amyloid oligomers and/or ⁇ -amyloid plaques and further deposits or Alzheimer's disease.
- a certain embodiment of the invention provides a compound of formula I as described herein for the use as therapeutically active substance for the therapeutic and/or prophylactic treatment of Alzheimer's disease.
- a certain embodiment of the invention provides a compound of formula I as described herein for the use as therapeutically active substance for the therapeutic and/or prophylactic treatment of diabetes or type 2 diabetes.
- a certain embodiment of the invention provides a compound of formula I as described herein for the use as therapeutically active substance for the therapeutic and/or prophylactic treatment of diabetes.
- a certain embodiment of the invention provides a compound of formula I as described herein for the use as therapeutically active substance for the therapeutic and/or prophylactic treatment of diabetes or type 2 diabetes.
- a certain embodiment of the invention provides a compound of formula I as described herein for the use as therapeutically active substance for the therapeutic and/or prophylactic treatment of Alzheimer's disease, diabetes or type 2 diabetes.
- a certain embodiment of the invention provides a pharmaceutical composition comprising a compound of formula I as described herein and a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable auxiliary substance.
- a certain embodiment of the invention provides the use of a compound of formula I as described herein for the manufacture of a medicament for the use in inhibition of BACEl and/or BACE2 activity.
- a certain embodiment of the invention provides the use of a compound of formula I as described herein for the manufacture of a medicament for the use in inhibition of BACEl activity.
- a certain embodiment of the invention provides the use of a compound of formula I as described herein for the manufacture of a medicament for the use in inhibition of BACE2 activity.
- a certain embodiment of the invention provides the use of a compound of formula I as described herein for the manufacture of a medicament for the use in inhibition of BACEl and BACE2 activity.
- a certain embodiment of the invention provides the use of a compound of formula I as described herein for the manufacture of a medicament for the therapeutic and/or prophylactic treatment of diseases and disorders characterized by elevated ⁇ -amyloid levels and/or ⁇ -amyloid oligomers and/or ⁇ -amyloid plaques and further deposits or Alzheimer's disease.
- a certain embodiment of the invention provides the use of a compound of formula I as described herein for the manufacture of a medicament for the therapeutic and/or prophylactic treatment of Alzheimer's disease.
- a certain embodiment of the invention provides the use of a compound of formula I as described herein for the manufacture of a medicament for the therapeutic and/or prophylactic treatment of diabetes or type 2 diabetes.
- a certain embodiment of the invention provides the use of a compound of formula I as described herein for the manufacture of a medicament for the therapeutic and/or prophylactic treatment of diabetes.
- a certain embodiment of the invention provides the use of a compound of formula I as described herein for the manufacture of a medicament for the therapeutic and/or prophylactic treatment of diabetes or type 2 diabetes.
- a certain embodiment of the invention provides the use of a compound of formula I as described herein for the manufacture of a medicament for the therapeutic and/or prophylactic treatment of Alzheimer's disease, diabetes or type 2 diabetes.
- a certain embodiment of the invention provides the use of a compound of formula I as described herein for the manufacture of a medicament for the therapeutic and/or prophylactic treatment of Alzheimer's disease.
- a certain embodiment of the invention provides the use of a compound of formula I as described herein for the manufacture of a medicament for the therapeutic and/or prophylactic treatment of diabetes or type 2 diabetes.
- a certain embodiment of the invention provides the use of a compound of formula I as described herein for the manufacture of a medicament for the therapeutic and/or prophylactic treatment of diabetes.
- a certain embodiment of the invention provides the use of a compound of formula I as described herein for the manufacture of a medicament for the therapeutic and/or prophylactic treatment of type 2 diabetes.
- a certain embodiment of the invention provides a compound of formula I as described herein for the use in inhibition of BACE1 and/or BACE2 activity.
- a certain embodiment of the invention provides a compound of formula I as described herein for the use in inhibition of BACE1 activity.
- a certain embodiment of the invention provides a compound of formula I as described herein for the use in inhibition of BACE2 activity.
- a certain embodiment of the invention provides a compound of formula I as described herein for the use in inhibition of BACE1 and BACE2 activity.
- a certain embodiment of the invention provides a compound of formula I as described herein for the use in the therapeutic and/or prophylactic treatment of diseases and disorders characterized by elevated ⁇ -amyloid levels and/or ⁇ -amyloid oligomers and/or ⁇ -amyloid plaques and further deposits or Alzheimer's disease.
- a certain embodiment of the invention provides a compound of formula I as described herein for the use in the therapeutic and/or prophylactic treatment of Alzheimer's disease.
- a certain embodiment of the invention provides a compound of formula I as described herein for the use in the therapeutic and/or prophylactic treatment of diabetes or type 2 diabetes.
- a certain embodiment of the invention provides a compound of formula I as described herein for the use in the therapeutic and/or prophylactic treatment of diabetes.
- a certain embodiment of the invention provides a compound of formula I as described herein for the use in the therapeutic and/or prophylactic treatment of diabetes or type 2 diabetes.
- a certain embodiment of the invention provides a compound of formula I as described herein for the use in the therapeutic and/or prophylactic treatment of Alzheimer's disease, diabetes or type 2 diabetes.
- a certain embodiment of the invention provides a method for the use in inhibition of BACEl and/or BACE2 activity, particularly for the therapeutic and/or prophylactic treatment of diseases and disorders characterized by elevated ⁇ -amyloid levels and/or ⁇ -amyloid oligomers and/or ⁇ -amyloid plaques and further deposits, Alzheimer's disease, diabetes or type 2 diabetes, which method comprises administering compound of formula I as described herein to a human being or animal.
- a certain embodiment of the invention provides a method for the use in the therapeutic and/or prophylactic treatment of Alzheimer's disease, diabetes or type 2 diabetes, which method comprises administering a compound of formula I as described herein to a human being or animal.
- a certain embodiment of the invention provides a method for the use in the therapeutic and/or prophylactic treatment of Alzheimer's disease, which method comprises administering a compound of formula I as described herein to a human being or animal.
- a certain embodiment of the invention provides a method for the use in the therapeutic and/or prophylactic treatment of diabetes, which method comprises administering a compound of formula I as described herein to a human being or animal.
- a certain embodiment of the invention provides a method for the use in the therapeutic and/or prophylactic treatment of type 2 diabetes, which method comprises administering a compound of formula I as described herein to a human being or animal.
- the invention includes all optical isomers, i.e. diastereoisomers, diastereomeric mixtures, racemic mixtures, all their corresponding enantiomers and/or tautomers as well as their solvates of the compounds of formula I.
- the compounds of formula I can contain one or more asymmetric centers and can therefore occur as racemates, racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. Additional asymmetric centers can be present depending upon the nature of the various substituents on the molecule. Each such asymmetric centre will independently produce two optical isomers and it is intended that all of the possible optical isomers and diastereomers in mixtures and as pure or partially purified compounds are included within this invention. The present invention is meant to encompass all such isomeric forms of these compounds. The independent syntheses of these diastereomers or their chromatographic separations can be achieved as known in the art by appropriate modification of the methodology disclosed herein.
- optically pure enantiomer means that the compound contains > 90 % of the desired isomer by weight, particularly > 95 % of the desired isomer by weight, or more particularly > 99 % of the desired isomer by weight, said weight percent based upon the total weight of the isomer(s) of the compound.
- Chirally pure or chirally enriched compounds can be prepared by chirally selective synthesis or by separation of enantiomers. The separation of enantiomers can be carried out on the final product or alternatively on a suitable intermediate.
- the compounds of formula I can be prepared in accordance with the following schemes.
- the starting material is commercially available or can be prepared in accordance with known methods. Any previously defined residues and variables will continue to have the previously defined meaning unless otherwise indicated.
- a titanium(IV)alkoxide more particularly titanium(IV)ethoxide in a solvent such as an ether, e.g. diethyl ether or more particularly tetrahydrofuran.
- a solvent such as an ether, e.g. diethyl ether or more particularly tetrahydrofuran.
- the conversion of the sulfinyl imine A2 to the sulfinamide ester A3 proceeds stereoselectively by the chiral directing group as described by Tang & Ellman.
- the sulfinyl imine A2 can be reacted in a Reformatsky reaction with a zinc enolate generated from e.g.
- an alkyl bromodifluoroacetate particularly ethyl bromodifluoroacetate
- activated zinc powder at ambient to elevated temperature, particularly at 23 to 60 °C in a solvent such as an ether, e.g. diethyl ether or more particularly tetrahydrofuran.
- the alcohol of formula A4 can be prepared by the reduction of an ethylester of formula A3 with an alkali hydride, particularly lithium borohydride or lithium aluminium hydride, in a solvent such as an ether, e.g. diethyl ether or more particularly tetrahydrofuran.
- Hydrolysis of the chiral directing group in the sulfinamide alcohol of formula A4 to give the aminoalcohol of formula A5 can be accomplished with a mineral acid, e.g. sulfuric acid or particularly hydrochloric acid, in a solvent such as an ether, e.g. diethyl ether, tetrahydrofuran or more particularly 1,4-dioxane.
- the aminooxazine of formula A6 can be prepared by reaction of an aminoalcohol of formula A5 with cyanogen bromide in a solvent such as an alcohol, particularly ethanol.
- anilines of formula A7 can be accomplished by hydrogenation using a catalyst, such as palladium on carbon, in protic solvents, such as alcohols, in particular ethanol or methanol.
- a catalyst such as palladium on carbon
- protic solvents such as alcohols, in particular ethanol or methanol.
- Target amines of formula 1.1 can be prepared by palladium-catalyzed cross coupling between compounds of formula A6 and derivatives of formula Z-R a , wherein R a has the meaning of a boronic acid or ester under conditions (Suzuki-Miyaura-coupling) known to those skilled in the art.
- Target amides of formula 1.2 can be prepared by selective coupling of anilines of formula A7 and a carboxylic acid of formula Z-COOH with 4-(4,6-dimethoxy[1.3.5]triazin-2-yl)-4- methylmorpholinium chloride hydrate (DMTMM) as the condensating agent in a solvent such as methanol.
- DTMM 4-(4,6-dimethoxy[1.3.5]triazin-2-yl)-4- methylmorpholinium chloride hydrate
- Protection of the amino group in compounds of formula A6, wherein Q is bromine, to produce aryl bromides of formula A6.1 can be performed with triarylmefhyl chlorides, such as triphenylmethyl chloride (Tr-Cl), p-methoxyphenyldiphenylmethyl chloride (MMTr-Cl), di(p- methoxyphenyl)phenylmethyl chloride (DMTr-Cl) or tri(p-methoxyphenyl)methyl chloride (TMTr-Cl), particularly DMTr-Cl, under basic conditions, e.g. in the presence of an amine, such as triethylamine or diisopropyle hylamine, in a chlorinated solvent, such as dichloromethane or chloroform, at temperatures between 0 °C and ambient temperature.
- Tr-Cl triarylmefhyl chlorides
- Aryl bromides of formula A6.1 can be reacted with ammonia equivalents, such as benzophenone imine, in the presence of a suitable transition metal catalyst, such as bis(dibenzylideneacetone)palladium (0) ((dba) 2 Pd) or tris(dibenzylideneacetone)dipalladium (0) ((dba) 3 Pd 2 )), and a suitable ligand, such as rac-2,2'-bis(diphenylphosphino)-l,l'-binaphthyl (rac- BINAP), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (X-PHOS) or 2-di-tert- butylphosphino-2',4',6'-triisopropylbiphenyl ( ⁇ -Bu X-PHOS), in the presence of a base, such as sodium ieri-butoxide, potassium
- Deprotection of both amino groups in compounds of formula A6.2 can be achieved by a one- pot procedure by first reacting it with a strong organic acid, such as trifluoroacetic acid, in chlorinated solvents, such as dichloromethane or chloroform, under anhydrous conditions at temperatures between 0 °C and ambient temperature to cleave the P ⁇ group. Then the addition of water to cleave the benzophenone imine and reaction at ambient temperature produces diamines of formula A7.
- a strong organic acid such as trifluoroacetic acid
- chlorinated solvents such as dichloromethane or chloroform
- P 1 e.g. Tr, MMTr, DMTr, TMTr
- an alkyl sulfinamide most particularly (R)-(+)-tert-butylsulfinamide
- a Lewis acid such as e.g. a titaniurn(IV)alkoxide, more particularly titanium(IV)ethoxide in a solvent such as an ether, e.g. diethyl ether or more particularly tetrahydrofuran.
- a solvent such as an ether, e.g. diethyl ether or more particularly tetrahydrofuran.
- the sulfinyl imine B2 can be reacted in a Reformatsky reaction with a zinc enolate generated from e.g. an alkyl bromodifluoroacetate, particularly ethyl bromodifluoroacetate, and activated zinc powder at ambient to elevated temperature, particularly at 23 to 60 °C in a solvent such as an ether, e.g. diethyl ether or more particularly tetrahydrofuran.
- a solvent such as an ether, e.g. diethyl ether or more particularly tetrahydrofuran.
- the alcohol of formula B4 can be prepared by the reduction of an ethylester of formula B3 with an alkali hydride, particularly lithium borohydride or lithium aluminium hydride, in a solvent such as an ether, e.g. diethyl ether or more particularly tetrahydrofuran.
- an alkali hydride particularly lithium borohydride or lithium aluminium hydride
- a solvent such as an ether, e.g. diethyl ether or more particularly tetrahydrofuran.
- Hydrolysis of the chiral directing group in the sulfinamide alcohol of formula B4 to give the aminoalcohol of formula B5 can be accomplished with a mineral acid, e.g. sulfuric acid or particularly hydrochloric acid, in a solvent such as an ether, e.g. diethyl ether, tetrahydrofuran or more particularly 1,4-dioxane.
- a mineral acid e.g. sulfuric acid or particularly hydrochloric acid
- a solvent such as an ether, e.g. diethyl ether, tetrahydrofuran or more particularly 1,4-dioxane.
- the aminooxazine of formula B6 can be prepared by reaction of an aminoalcohol of formula B5 with cyanogen bromide in a solvent such as an alcohol, particularly ethanol.
- anilines of formula B7 can be accomplished by hydrogenation using a catalyst, such as palladium on carbon, in protic solvents, such as alcohols, in particular ethanol or methanol.
- a catalyst such as palladium on carbon
- protic solvents such as alcohols, in particular ethanol or methanol.
- Target amines of formula 1.3 can be prepared by palladium-catalyzed cross coupling between compounds of formula B6 and derivatives of formula Z-R a , wherein R a has the meaning of a boronic acid or ester under conditions (Suzuki-Miyaura-coupling) known to those skilled in the art.
- Target amides of formula 1.4 can be prepared by selective coupling of anilines of formula B7 and a carboxylic acid of formula Z-COOH with 4-(4,6-dimethoxy[1.3.5]triazin-2-yl)-4- methylmorpholinium chloride hydrate (DMTMM) as the condensating agent in a solvent such as methanol.
- DTMM 4-(4,6-dimethoxy[1.3.5]triazin-2-yl)-4- methylmorpholinium chloride hydrate
- Target amides of formula 1.3 or 1.4, wherein X is SO 2 can be prepared from compounds of formula 1.3 or 1.4, wherein X is S, by oxidation in inert solvents at temperatures between 0 °C and ambient temperature using e.g. potassium peroxomonosulphate as the oxidizing agent.
- anilines of formula B7 can be prepared via N-protected intermediates as illustrated in Scheme B.l.
- aryl bromides of formula B6.1 Protection of the amino group in compounds of formula A6, wherein Q is bromine, to produce aryl bromides of formula B6.1 can be performed with triarylmefhyl chlorides, such as triphenylmethyl chloride (Tr-Cl), p-methoxyphenyldiphenylmethyl chloride (MMTr-Cl), di(p- methoxyphenyl)phenylmethyl chloride (DMTr-Cl) or tri(p-methoxyphenyl)methyl chloride (TMTr-Cl), particularly DMTr-Cl, under basic conditions, e.g.
- Tr-Cl triphenylmethyl chloride
- MMTr-Cl p-methoxyphenyldiphenylmethyl chloride
- DMTr-Cl di(p- methoxyphenyl)phenylmethyl chloride
- TMTr-Cl tri(p-methoxyphenyl)methyl chloride
- TMTr-Cl tri
- Aryl bromides of formula B6.1 can be reacted with ammonia equivalents, such as benzophenone imine, in the presence of a suitable transition metal catalyst, such as bis(dibenzylideneacetone)palladium (0) ((dba) 2 Pd) or tris(dibenzylideneacetone)dipalladium (0) ((dba) 3 Pd 2 )), and a suitable ligand, such as rac-2,2'-bis(diphenylphosphino)-l,l'-binaphthyl (rac- BINAP), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (X-PHOS) or 2-di-ter
- Deprotection of both amino groups in compounds of formula B6.2 can be achieved by a one- pot procedure by first reacting it with a strong organic acid, such as trifluoroacetic acid, in chlorinated solvents, such as dichloromethane or chloroform, under anhydrous conditions at temperatures between 0 °C and ambient temperature to cleave the P ⁇ group. Then the addition of water to cleave the benzophenone imine and reaction at ambient temperature produces diamines of formula B7.
- a strong organic acid such as trifluoroacetic acid
- chlorinated solvents such as dichloromethane or chloroform
- Alkylation of alcohols of formula A4 or B4 to nitriles of formula CI can be accomplished with a suitable mild base particularly silver(I) oxide in a solvent such as tetrahydrofuran or dichloromethane, more particularly dichloromethane, in the presence of an alkylating catalyst such as tetra-butyl ammonium iodide.
- a suitable mild base particularly silver(I) oxide
- a solvent such as tetrahydrofuran or dichloromethane, more particularly dichloromethane
- an alkylating catalyst such as tetra-butyl ammonium iodide.
- Hydrolysis of the chiral directing group in nitriles of formula CI to give amino nitriles of formula C2 can be accomplished with a mineral acid, e.g. sulfuric acid or particularly hydrochloric acid in a solvent such as an ether, e.g. diethyl ether or more particularly 1,4-dioxane.
- Aminooxazepines of formula C3 can be prepared by the reaction of amino nitriles of formula C2 and trimethyl aluminium in a solvent such as a xylene or toluene, particularly toluene.
- anilines of formula C4 can be accomplished by hydrogenation using a catalyst, such as palladium on carbon, in protic solvents, such as alcohols, in particular ethanol or methanol.
- a catalyst such as palladium on carbon
- protic solvents such as alcohols, in particular ethanol or methanol.
- Target amines of formula 1.5 can be prepared by palladium-catalyzed cross coupling between compounds of formula C3 and derivatives of formula Z-R a , wherein R a has the meaning of a boronic acid or ester under conditions (Suzuki-Miyaura-coupling) known to those skilled in the art.
- Target amides of formula 1.6 can be prepared by selective coupling of anilines of formula C4 and a carboxylic acid of formula Z-COOH with 4-(4,6-dimethoxy[1.3.5]triazin-2-yl)-4- methylmorpholinium chloride hydrate (DMTMM) as the condensating agent in a solvent such as methanol.
- DTMM methylmorpholinium chloride hydrate
- the corresponding pharmaceutically acceptable salts with acids can be obtained by standard methods known to the person skilled in the art, e.g. by dissolving the compound of formula I in a suitable solvent such as e.g. dioxane or tetrahydrofuran (THF) and adding an appropriate amount of the corresponding acid.
- a suitable solvent such as e.g. dioxane or tetrahydrofuran (THF)
- THF tetrahydrofuran
- the products can usually be isolated by filtration or by chromatography.
- the conversion of a compound of formula I into a pharmaceutically acceptable salt with a base can be carried out by treatment of such a compound with such a base.
- One possible method to form such a salt is e.g. by addition of 1/n equivalents of a basic salt such as e.g.
- a suitable solvent e.g. ethanol, ethanol-water mixture, tetrahydrofuran-water mixture
- Particular salts are hydrochloride, formate and trifluoroacetate.
- the compounds of formula I as well as all intermediate products can be prepared according to analogous methods or according to the methods set forth herein. Starting materials are commercially available, known in the art or can be prepared by methods known in the art or in analogy thereto. It will be appreciated that the compounds of general formula I in this invention can be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compound in vivo.
- the compounds of formula I and their pharmaceutically acceptable salts possess valuable pharmacological properties. It has been found that the compounds of the present invention are associated with inhibition of BACE1 and/or BACE2 activity. The compounds were investigated in accordance with the test given hereinafter.
- Cellular ⁇ -lo ering assay a) Human HEK293 cells which are stably transfected with a vector expressing a cDNA of the human APP wt gene (APP695) were used to assess the potency of the compounds in a cellular assay. The cells were seeded in 96-well microtiter plates in cell culture medium (Iscove, plus 10% (v/v) fetal bovine serum, glutamine, penicillin/streptomycin) to about 80% confluence and the compounds were added at a lOx concentration in 1/10 volume of medium without FCS containing 8% DMSO (final concentration of DMSO was kept at 0.8% v/v).
- cell culture medium Iscove, plus 10% (v/v) fetal bovine serum, glutamine, penicillin/streptomycin
- ⁇ 40 concentrations were harvested for the determination of ⁇ 40 concentrations.
- 96well ELISA plates e.g., Nunc MaxiSorb
- monoclonal antibody which specifically recognize the C-terminal end of ⁇ 40 (Brockhaus et al., NeuroReport 9, 1481-1486; 1998).
- the culture supernatants were added in suitable dilutions together with a horseradish peroxidase-coupled ⁇ detection antibody (e.g., antibody 4G8, Senetek, Maryland Heights, MO) and incubated for 5 to 7 hrs.
- a horseradish peroxidase-coupled ⁇ detection antibody e.g., antibody 4G8, Senetek, Maryland Heights, MO
- the wells of the microtiter plate were washed extensively with Tris-buffered saline containing 0.05% Tween 20 and the assay was developed with tetramethylbenzidine/H 2 0 2 in citric acid buffer. After stopping the reaction with one volume of IN H 2 SO 4 the reaction was measured in an ELISA reader at 450 nm wavelength. The concentrations of ⁇ in the culture supernatants were calculated from a standard curve obtained with known amounts of pure ⁇ peptide. b) Alternatively, the Abeta 40 AlphaLISA Assay can be used.
- the HEK293 APP cells were seeded in 96 well Microtiter plates in cell culture medium (Iscove's, plus 10% (v/v) fetal bovine serum, penicillin/streptomycin ) to about 80% confluency and the compounds were added at a 3x concentration in 1/3 volume of culture medium ( final DMSO concentration was kept at 1 % v/v). After 18-20 hrs incubation at 37 °C and 5% C0 2 in a humidified incubator, the culture supernatants were harvested for the determination of ⁇ 40 concentrations using Perkin-Elmer Human Amyloid beta 1-40 ( high specificity ) Kit ( Cat# AL275C ).
- the assay uses the principle of inhibition of human TMEM27 cleavage by endogenous cellular BACE2 in the Insle rat cell line and shedding from the cell surface into the culture medium, followed by detection in an ELISA assay. Inhibition of BACE2 prevents the cleavage and shedding in a dose-dependent manner.
- the stable cell line "INS-TMEM27” represents an INSle-derived cell line with inducible expression (using the TetOn system) of full-length hTMEM27 in a doxycycline-dependent manner.
- the cells are cultured throughout the experiment in RPMI1640 + Glutamax (Invitrogen) Penicillin/Streptomycin, 10% Fetal bovine serum, 100 mM pyruvate, 5 mM beta- mercatptoethanol, 100 micrograms/ml G418 and 100 micro gram/ml hygromycin and are grown inadherent culture at 37 °C in a standard C0 2 cell culture incubator.
- INS-TMEM27 cells are seeded in 96-well plates. After 2 days in culture, BACE2 inhibitor is added in a range of concentrations as required by the assay and after a further two hours, doxycycline is added to a final concentration of 500 ng/ml. The cells are incubated for a further 46 hours and the supernatant harvested for detection of shed TMEM27.
- An ELISA assay (using a pair of mouse anti-human-TMEM27 antibodies, raised against the extracellular domain of TMEM27) is used for detection of TMEM27 in the culture medium.
- An EC 50 for BACE2 inhibition is calculated using the ELISA readout for each inhibitor concentration with standard curve-fitting software such as XLFit for the Excel spreadsheet program.
- Table 1 IC 50 values of selected examples, a) and ' indicate the respective cellular assay used
- the compounds of formula I and the pharmaceutically acceptable salts can be used as therapeutically active substances, e.g. in the form of pharmaceutical preparations.
- the pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatin capsules, solutions, emulsions or suspensions.
- the administration can, however, also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.
- the compounds of formula I and the pharmaceutically acceptable salts thereof can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations.
- Lactose, corn starch or derivatives thereof, talc, stearic acids or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragees and hard gelatin capsules.
- Suitable carriers for soft gelatin capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Depending on the nature of the active substance no carriers are however usually required in the case of soft gelatin capsules.
- Suitable carriers for the production of solutions and syrups are, for example, water, polyols, glycerol, vegetable oil and the like.
- Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.
- the pharmaceutical preparations can, moreover, contain pharmaceutically acceptable auxiliary substances such as preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
- pharmaceutically acceptable auxiliary substances such as preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
- Medicaments containing a compound of formula I or a pharmaceutically acceptable salt thereof and a therapeutically inert carrier are also provided by the present invention, as is a process for their production, which comprises bringing one or more compounds of formula I and/or pharmaceutically acceptable salts thereof and, if desired, one or more other therapeutically valuable substances into a galenical administration form together with one or more therapeutically inert carriers.
- the dosage can vary within wide limits and will, of course, have to be adjusted to the individual requirements in each particular case.
- the dosage for adults can vary from about 0.01 mg to about 1000 mg per day of a compound of general formula I or of the corresponding amount of a pharmaceutically acceptable salt thereof.
- the daily dosage can be administered as single dose or in divided doses and, in addition, the upper limit can also be exceeded when this is found to be indicated.
- compositions according to the invention are:
- the compound of formula I, lactose and corn starch are firstly mixed in a mixer and then in a comminuting machine.
- the mixture is returned to the mixer; the talc is added thereto and mixed thoroughly.
- the mixture is filled by machine into suitable capsules, e.g. hard gelatin capsules.
- the compound of formula I is dissolved in a warm melting of the other ingredients and the mixture is filled into soft gelatin capsules of appropriate size.
- the filled soft gelatin capsules are treated according to the usual procedures.
- the suppository mass is melted in a glass or steel vessel, mixed thoroughly and cooled to 45°C. Thereupon, the finely powdered compound of formula I is added thereto and stirred until it has dispersed completely. The mixture is poured into suppository moulds of suitable size, left to cool; the suppositories are then removed from the moulds and packed individually in wax paper or metal foil.
- the compound of formula I is dissolved in a mixture of Polyethylene Glycol 400 and water for injection (part).
- the pH is adjusted to 5.0 by acetic acid.
- the volume is adjusted to 1.0 ml by addition of the residual amount of water.
- the solution is filtered, filled into vials using an appropriate overage and sterilized.
- the compound of formula I is mixed with lactose, microcrystalline cellulose and sodium carboxymethyl cellulose and granulated with a mixture of polyvinylpyrrolidone in water.
- the granulate is mixed with magnesium stearate and the flavoring additives and filled into sachets.
- MS Mass spectra (MS) were measured either with ion spray positive or negative (ISP or ISN) method on a Perkin-Elmer SCIEX API 300 or with electron impact method (EI, 70 eV) on a Finnigan MAT SSQ 7000 spectrometer. Synthesis of the intermediate sulfinyl imines A2
- the 6'-bromo-3',4'-dihydro-2'H-spiro[[l,3]dithiolane-2,r- naphthalene] (1.06 g, 88% yield) was obtained as a light red oil.
- the dark red solution was poured into a mixture of hexane (50 ml) and dichloromethane (10 ml).
- the deeply colored solution was first passed through a layer of silica gel, then through a layer of a silica-NH2 phase and Dicalite®.
- the 6-bromo-l,l-difluoro-l,2,3,4-tetrahydro-naphthalene (668 mg, 68% yield) was obtained as a pale yellow oil.
- the mixture was diluted with ethyl acetate (200 ml), the organic layer separated, washed with water (10 ml) and brine (10 ml), finally dried over sodium sulphate and evaporated at reduced pressure.
- the 7-bromo-4,4-difluoro-3,4-dihydro-2H-naphthalen-l-one (515 mg, 71% yield) was obtained as a colorless oil.
- a dried tube was charged with a mixture of the amino alcohol A5 (18.8 mmol), cyanogen bromide (33.9 mmol) and ethanol (61 ml). The tube was sealed and heated at 90 °C for 16 hours. For the workup, the reaction mixture was cooled and evaporated at reduced pressure. The residue was partitioned between ethyl acetate (150 ml) and a saturated aqueous solution of sodium carbonate (50 ml). The aqueous layer was separated and re -extracted with ethyl acetate (2 x 50 ml). The organic layers were washed with brine (50 ml), then combined, dried over sodium sulphate and evaporated at reduced pressure. The product was used in the next step without further purification.
- reaction mixture was poured into a solution of sodium carbonate (1M) followed by the extraction with ethyl acetate. The organic layer was separated, washed with brine and dried over sodium sulphate. Removal of the solvent at reduced pressure left a residue which was purified by chromatography on silica gel or on a silica-NH 2 phase using a mixture of dichloromethane and methanol (0-10%) to give the pure amides of formula I.
- reaction mixture was poured into a solution of sodium carbonate (1M) followed by the extraction with ethyl acetate. The organic layer was separated, washed with brine and dried over sodium sulphate. Removal of the solvent at reduced pressure left a residue which was purified by chromatography on silica gel or on a silica-NH 2 phase using a mixture of dichloromethane and methanol (0-10%) to give the pure amides of formula I.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2013013910A MX2013013910A (en) | 2011-05-27 | 2012-05-24 | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as bace1 and/or bace2 inhibitors. |
CN201280025801.2A CN103596961B (en) | 2011-05-27 | 2012-05-24 | Spiral shell-[1,3]-* piperazine and spiral shell-[1,4]-oxygen azepine * as BACE1 and/or BACE2 inhibitor |
SG2013082607A SG194835A1 (en) | 2011-05-27 | 2012-05-24 | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as bace1 and/or bace2 inhibitors |
ES12724116.4T ES2600636T3 (en) | 2011-05-27 | 2012-05-24 | Spiro- [1,3] -oxazines and spiro- [1,4] -oxazepines as inhibitors of BACE1 and / or BACE2 |
NZ616817A NZ616817B2 (en) | 2011-05-27 | 2012-05-24 | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as bace1 and/or bace2 inhibitors |
EA201391752A EA024286B1 (en) | 2011-05-27 | 2012-05-24 | Spiro[1,3]oxazines and spiro[1,4]oxazepines as bace1 and/or bace2 inhibitors |
CA2833813A CA2833813A1 (en) | 2011-05-27 | 2012-05-24 | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as bace1 and/or bace2 inhibitors |
UAA201315118A UA111847C2 (en) | 2011-05-27 | 2012-05-24 | SPIRO- [1,3] -OXASINS AND SPIRO- [1,4] -OXASEPSIN AS BACE1 AND (OR) BACE2 INHIBITORS |
AU2012264875A AU2012264875B2 (en) | 2011-05-27 | 2012-05-24 | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors |
JP2014513129A JP2014515382A (en) | 2011-05-27 | 2012-05-24 | Spiro- [1,3] -oxazine and spiro- [1,4] -oxazepine derivatives as BACE1 and / or BACE2 inhibitors |
BR112013030281A BR112013030281A2 (en) | 2011-05-27 | 2012-05-24 | spiro- [1,3] oxoxins and spiro- [1,4] oxazepines as inhibitors of bace1 and / or bace2 |
KR1020137033959A KR20140048137A (en) | 2011-05-27 | 2012-05-24 | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as bace1 and/or bace2 inhibitors |
EP12724116.4A EP2714697B1 (en) | 2011-05-27 | 2012-05-24 | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as bace1 and/or bace2 inhibitors |
ZA2013/08395A ZA201308395B (en) | 2011-05-27 | 2013-11-07 | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as bace1 and/orbace2 inhibitors |
IL229334A IL229334A (en) | 2011-05-27 | 2013-11-07 | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as bace1 and/or bace2 inhibitors |
MA36582A MA35191B1 (en) | 2011-05-27 | 2013-12-18 | Spiro- [1,3] -oxazines and spiro- [1,4] -oxazepines as inhibitors of baec1 and / or bace2 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11167835 | 2011-05-27 | ||
EP11167835.5 | 2011-05-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012163790A1 true WO2012163790A1 (en) | 2012-12-06 |
Family
ID=46177417
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2012/059688 WO2012163790A1 (en) | 2011-05-27 | 2012-05-24 | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as bace1 and/or bace2 inhibitors |
Country Status (22)
Country | Link |
---|---|
US (1) | US9079919B2 (en) |
EP (1) | EP2714697B1 (en) |
JP (1) | JP2014515382A (en) |
KR (1) | KR20140048137A (en) |
CN (1) | CN103596961B (en) |
AU (1) | AU2012264875B2 (en) |
BR (1) | BR112013030281A2 (en) |
CA (1) | CA2833813A1 (en) |
CL (1) | CL2013003372A1 (en) |
CO (1) | CO6801773A2 (en) |
CR (1) | CR20130580A (en) |
EA (1) | EA024286B1 (en) |
EC (1) | ECSP13013048A (en) |
ES (1) | ES2600636T3 (en) |
IL (1) | IL229334A (en) |
MA (1) | MA35191B1 (en) |
MX (1) | MX2013013910A (en) |
PE (1) | PE20141205A1 (en) |
SG (1) | SG194835A1 (en) |
UA (1) | UA111847C2 (en) |
WO (1) | WO2012163790A1 (en) |
ZA (1) | ZA201308395B (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8541408B2 (en) | 2007-04-24 | 2013-09-24 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives substituted with a cyclic group |
US8546380B2 (en) | 2005-10-25 | 2013-10-01 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives |
US8637504B2 (en) | 2008-06-13 | 2014-01-28 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity |
US8653067B2 (en) | 2007-04-24 | 2014-02-18 | Shionogi & Co., Ltd. | Pharmaceutical composition for treating Alzheimer's disease |
US8703785B2 (en) | 2008-10-22 | 2014-04-22 | Shionogi & Co., Ltd. | 2-aminopyrimidin-4-one and 2-aminopyridine derivatives both having BACE1-inhibiting activity |
US8883779B2 (en) | 2011-04-26 | 2014-11-11 | Shinogi & Co., Ltd. | Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them |
US8927721B2 (en) | 2010-10-29 | 2015-01-06 | Shionogi & Co., Ltd. | Naphthyridine derivative |
US8975415B2 (en) | 2012-05-30 | 2015-03-10 | Comentis, Inc. | Chromane compounds |
US8999980B2 (en) | 2009-12-11 | 2015-04-07 | Shionogi & Co., Ltd. | Oxazine derivatives |
US9018219B2 (en) | 2010-10-29 | 2015-04-28 | Shionogi & Co., Ltd. | Fused aminodihydropyrimidine derivative |
WO2016055858A1 (en) * | 2014-10-07 | 2016-04-14 | Astrazeneca Ab | Compounds and their use as bace inhibitors |
WO2016150785A1 (en) | 2015-03-20 | 2016-09-29 | F. Hoffmann-La Roche Ag | Bace1 inhibitors |
US9540359B2 (en) | 2012-10-24 | 2017-01-10 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8557826B2 (en) | 2009-10-08 | 2013-10-15 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use |
US8563543B2 (en) | 2009-10-08 | 2013-10-22 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
UA108363C2 (en) | 2009-10-08 | 2015-04-27 | IMINOTIADIASIADIOXIDE OXIDES AS BACE INHIBITORS, COMPOSITIONS THEREOF AND THEIR APPLICATIONS | |
EP2485920B1 (en) | 2009-10-08 | 2016-04-27 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
EP2694489B1 (en) | 2011-04-07 | 2017-09-06 | Merck Sharp & Dohme Corp. | C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
WO2012138590A1 (en) | 2011-04-07 | 2012-10-11 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
MX2014002113A (en) | 2011-08-22 | 2014-04-25 | Merck Sharp & Dohme | 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use. |
WO2014099788A1 (en) | 2012-12-21 | 2014-06-26 | Merck Sharp & Dohme Corp. | C5-spiro iminothiadiazine dioxides as bace inhibitors |
TW201446758A (en) | 2013-03-01 | 2014-12-16 | Amgen Inc | Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
WO2014138484A1 (en) | 2013-03-08 | 2014-09-12 | Amgen Inc. | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
EP3043802B1 (en) | 2013-09-13 | 2018-04-18 | Merck Sharp & Dohme Corp. | C5-spiro iminothiazine dioxides as bace inhibitors, compositions, and their use |
AU2015301028B2 (en) | 2014-08-08 | 2019-09-26 | Amgen Inc. | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003095430A1 (en) | 2002-05-09 | 2003-11-20 | Pharmacia Corporation | Substituted pyrazolyl compounds for the treatment of inflammation |
WO2010013794A1 (en) * | 2008-07-28 | 2010-02-04 | Eisai R&D Management Co., Ltd. | Spiroaminodihydrothiazine derivatives |
WO2010021680A2 (en) | 2008-08-19 | 2010-02-25 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
WO2011123674A1 (en) * | 2010-03-31 | 2011-10-06 | Array Biopharma Inc. | Compounds for treating neurodegenerative diseases |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200624426A (en) * | 2004-09-21 | 2006-07-16 | Lilly Co Eli | BACE inhibitors |
EP1910364B1 (en) * | 2005-07-18 | 2012-03-21 | Merck Sharp & Dohme Corp. | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease |
CN103936690B (en) * | 2005-10-25 | 2016-06-08 | 盐野义制药株式会社 | Aminodihydrothiazinederivative derivative |
WO2008030412A2 (en) | 2006-09-07 | 2008-03-13 | Merck & Co., Inc. | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease |
JP5383483B2 (en) | 2007-04-24 | 2014-01-08 | 塩野義製薬株式会社 | Pharmaceutical composition for the treatment of Alzheimer's disease |
CN102186841A (en) * | 2008-10-22 | 2011-09-14 | 盐野义制药株式会社 | 2-aminopyridin-4-one and 2-aminopyridine derivative both having bace1-inhibiting activity |
WO2010073078A2 (en) | 2008-12-22 | 2010-07-01 | Orchid Research Laboratories Ltd. | Heterocyclic compounds as hdac inhibitors |
US8461160B2 (en) * | 2009-05-08 | 2013-06-11 | Hoffmann-La Roche, Inc. | Dihydropyrimidinones |
AR077328A1 (en) * | 2009-07-24 | 2011-08-17 | Novartis Ag | DERIVATIVES OF OXAZINE AND ITS USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS |
US8188079B2 (en) * | 2009-08-19 | 2012-05-29 | Hoffman-La Roche Inc. | 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines |
WO2011058763A1 (en) * | 2009-11-13 | 2011-05-19 | 塩野義製薬株式会社 | Aminothiazine or aminooxazine derivative having amino linker |
US7964594B1 (en) * | 2009-12-10 | 2011-06-21 | Hoffmann-La Roche Inc. | Amino oxazine derivatives |
UA103272C2 (en) * | 2009-12-11 | 2013-09-25 | Ф. Хоффманн-Ля Рош Аг | 2-amino-5,5-difluoro-5,6-dihydro-4h-[1,3]oxazines as bace1 and/or bace2 inhibitors |
JP2012250933A (en) * | 2011-06-03 | 2012-12-20 | Shionogi & Co Ltd | Pharmaceutical composition containing oxazine derivative for treating or preventing alzheimer's disease |
-
2012
- 2012-05-21 US US13/476,094 patent/US9079919B2/en not_active Expired - Fee Related
- 2012-05-24 ES ES12724116.4T patent/ES2600636T3/en active Active
- 2012-05-24 JP JP2014513129A patent/JP2014515382A/en active Pending
- 2012-05-24 UA UAA201315118A patent/UA111847C2/en unknown
- 2012-05-24 SG SG2013082607A patent/SG194835A1/en unknown
- 2012-05-24 WO PCT/EP2012/059688 patent/WO2012163790A1/en active Application Filing
- 2012-05-24 MX MX2013013910A patent/MX2013013910A/en unknown
- 2012-05-24 CA CA2833813A patent/CA2833813A1/en not_active Abandoned
- 2012-05-24 AU AU2012264875A patent/AU2012264875B2/en not_active Expired - Fee Related
- 2012-05-24 CN CN201280025801.2A patent/CN103596961B/en not_active Expired - Fee Related
- 2012-05-24 EP EP12724116.4A patent/EP2714697B1/en not_active Not-in-force
- 2012-05-24 BR BR112013030281A patent/BR112013030281A2/en not_active IP Right Cessation
- 2012-05-24 KR KR1020137033959A patent/KR20140048137A/en not_active Application Discontinuation
- 2012-05-24 EA EA201391752A patent/EA024286B1/en not_active IP Right Cessation
- 2012-05-24 PE PE2013002577A patent/PE20141205A1/en not_active Application Discontinuation
-
2013
- 2013-11-07 IL IL229334A patent/IL229334A/en not_active IP Right Cessation
- 2013-11-07 ZA ZA2013/08395A patent/ZA201308395B/en unknown
- 2013-11-07 CR CR20130580A patent/CR20130580A/en unknown
- 2013-11-13 CO CO13267226A patent/CO6801773A2/en not_active Application Discontinuation
- 2013-11-25 CL CL2013003372A patent/CL2013003372A1/en unknown
- 2013-11-25 EC ECSP13013048 patent/ECSP13013048A/en unknown
- 2013-12-18 MA MA36582A patent/MA35191B1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003095430A1 (en) | 2002-05-09 | 2003-11-20 | Pharmacia Corporation | Substituted pyrazolyl compounds for the treatment of inflammation |
WO2010013794A1 (en) * | 2008-07-28 | 2010-02-04 | Eisai R&D Management Co., Ltd. | Spiroaminodihydrothiazine derivatives |
WO2010021680A2 (en) | 2008-08-19 | 2010-02-25 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
WO2011123674A1 (en) * | 2010-03-31 | 2011-10-06 | Array Biopharma Inc. | Compounds for treating neurodegenerative diseases |
Non-Patent Citations (22)
Title |
---|
"IUPAC - Compendium of Chemical Terminology", 1997, BLACKWELL SCIENTIFIC PUBLICATIONS |
BIOCHEM. PHARMACOL, vol. 22, 1973, pages 3099 |
BROCKHAUS ET AL., NEUROREPORT, vol. 9, 1998, pages 1481 - 1486 |
E. HASLAM: "Protective Groups in Organic Chemistry", 1973, PLENUM PRESS |
G FINZI; F FRANZI; C PLACIDI; F ACQUATI ET AL.: "BACE2 is stored in secretory granules of mouse and rat pancreatic beta cells", ULTRASTRUCT PATHOL., vol. 32, no. 6, 2008, pages 246 - 251 |
HARDY ET AL.: "The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics", SCIENCE, vol. 297, no. 5580, 19 July 2002 (2002-07-19), pages 353 - 6 |
I HUSSAIN; D POWELL; D HOWLETT; G CHAPMAN ET AL.: "ASP1 (BACE2) cleaves the amyloid precursor protein at the ?-secretase site", MOL CELL NEUROSCI., vol. 16, 2000, pages 609 - 619, XP002589910, DOI: doi:10.1006/MCNE.2000.0884 |
K FUKUI; Q YANG; Y CAO; N TAKAHASHI ET AL.: "The HNF-1 target Collectrin controls insulin exocytosis by SNARE complex formation", CELL METAB., vol. 2, 2005, pages 373 - 384, XP055002289, DOI: doi:10.1016/j.cmet.2005.11.003 |
LL BAGGIO; DJ DRUCKER: "Therapeutic approaches to preserve islet mass in type 2 diabetes", ANNU. REV. MED., vol. 57, 2006, pages 265 - 281 |
LUO ET AL.: "Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation", NAT NEUROSCI., vol. 4, no. 3, March 2001 (2001-03-01), pages 231 - 2, XP002350002, DOI: doi:10.1038/85059 |
M PRENTKI; CJ NOLAN: "Islet beta-cell failure in type 2 diabetes", J. CLIN. INVESTIG., vol. 116, no. 7, 2006, pages 1802 - 1812 |
MCCONLOGUE ET AL.: "Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice", J BIOL CHEM., vol. 282, no. 36, 7 September 2007 (2007-09-07), pages 26326, XP055244703, DOI: doi:10.1074/jbc.M611687200 |
P AKPINAR; S KUWAJIMA; J KRIITZFELDT; M STOFFEL: "Tmem27: A cleaved and shed plasma membrane protein that stimulates pancreatic ? cell proliferation", CELL METAB., vol. 2, 2005, pages 385 - 397 |
P KUHN; E MARJAUX; A IMHOF; B DE STROOPER ET AL.: "Regulated intramembrane proteolysis of the interleukin-1 receptor II by alpha-, beta-, and gamma-secretase", J. BIOL. CHEM., vol. 282, no. 16, 2007, pages 11982 - 11995 |
P ZIMMET; KGMM ALBERTI; J SHAW: "Global and societal implications of the diabetes epidemic", NATURE, vol. 414, 2001, pages 782 - 787, XP055047466, DOI: doi:10.1038/414782a |
ROBERDS ET AL.: "BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics", HUM MOL GENET, vol. 10, no. 12, 1 June 2001 (2001-06-01), pages 1317 - 24, XP002228077, DOI: doi:10.1093/hmg/10.12.1317 |
S WILD; G ROGLIC; A GREEN; R.SICREE; H KING: "Global prevalence of diabetes", DIABETES CARE, vol. 27, no. 5, 2004, pages 1047 - 1053 |
SELKOE: "Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease", ANNU REV CELL BIOL., vol. 10, 1994, pages 373 - 403 |
T. W. GREENE; P. G. M. WUTS: "Protective Groups in Organic Synthesis", 1991, JOHN WILEY & SONS, INC. |
T.P. TANG; J.A. ELLMAN, J. ORG. CHEM., vol. 64, 1999, pages 12 |
T.W. GREENE: "Protective Groups in Organic Synthesis", 1981, JOHN WILEY AND SONS |
VASSAR ET AL.: "Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE", SCIENCE, vol. 286, no. 5440, 22 October 1999 (1999-10-22), pages 735, XP000914811, DOI: doi:10.1126/science.286.5440.735 |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8546380B2 (en) | 2005-10-25 | 2013-10-01 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives |
US8633188B2 (en) | 2005-10-25 | 2014-01-21 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives |
US8815851B2 (en) | 2005-10-25 | 2014-08-26 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives |
US9029358B2 (en) | 2005-10-25 | 2015-05-12 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives |
US8541408B2 (en) | 2007-04-24 | 2013-09-24 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives substituted with a cyclic group |
US8653067B2 (en) | 2007-04-24 | 2014-02-18 | Shionogi & Co., Ltd. | Pharmaceutical composition for treating Alzheimer's disease |
US8884062B2 (en) | 2007-04-24 | 2014-11-11 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives substituted with a cyclic group |
US8895548B2 (en) | 2007-04-24 | 2014-11-25 | Shionogi & Co., Ltd. | Pharmaceutical composition for treating alzheimer's disease |
US8637504B2 (en) | 2008-06-13 | 2014-01-28 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity |
US9650371B2 (en) | 2008-06-13 | 2017-05-16 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity |
US9273053B2 (en) | 2008-06-13 | 2016-03-01 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having Beta secretase inhibitory activity |
US8703785B2 (en) | 2008-10-22 | 2014-04-22 | Shionogi & Co., Ltd. | 2-aminopyrimidin-4-one and 2-aminopyridine derivatives both having BACE1-inhibiting activity |
US8999980B2 (en) | 2009-12-11 | 2015-04-07 | Shionogi & Co., Ltd. | Oxazine derivatives |
US9290466B2 (en) | 2009-12-11 | 2016-03-22 | Shionogi & Co., Ltd. | Oxazine derivatives |
US9656974B2 (en) | 2009-12-11 | 2017-05-23 | Shionogi & Co., Ltd. | Oxazine derivatives |
US9018219B2 (en) | 2010-10-29 | 2015-04-28 | Shionogi & Co., Ltd. | Fused aminodihydropyrimidine derivative |
US8927721B2 (en) | 2010-10-29 | 2015-01-06 | Shionogi & Co., Ltd. | Naphthyridine derivative |
US8883779B2 (en) | 2011-04-26 | 2014-11-11 | Shinogi & Co., Ltd. | Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them |
US8975415B2 (en) | 2012-05-30 | 2015-03-10 | Comentis, Inc. | Chromane compounds |
US9242973B2 (en) | 2012-05-30 | 2016-01-26 | Comentis, Inc. | Chromane compounds |
US9540359B2 (en) | 2012-10-24 | 2017-01-10 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity |
US9758513B2 (en) | 2012-10-24 | 2017-09-12 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity |
WO2016055858A1 (en) * | 2014-10-07 | 2016-04-14 | Astrazeneca Ab | Compounds and their use as bace inhibitors |
US10053453B2 (en) | 2014-10-07 | 2018-08-21 | Astrazeneca Ab | Compounds and their use as BACE inhibitors |
WO2016150785A1 (en) | 2015-03-20 | 2016-09-29 | F. Hoffmann-La Roche Ag | Bace1 inhibitors |
Also Published As
Publication number | Publication date |
---|---|
MA35191B1 (en) | 2014-06-02 |
PE20141205A1 (en) | 2014-09-22 |
CN103596961B (en) | 2016-09-28 |
US20120302549A1 (en) | 2012-11-29 |
EP2714697B1 (en) | 2016-08-31 |
NZ616817A (en) | 2015-12-24 |
MX2013013910A (en) | 2014-01-24 |
SG194835A1 (en) | 2013-12-30 |
US9079919B2 (en) | 2015-07-14 |
UA111847C2 (en) | 2016-06-24 |
CN103596961A (en) | 2014-02-19 |
EA024286B1 (en) | 2016-09-30 |
CL2013003372A1 (en) | 2014-07-25 |
CO6801773A2 (en) | 2013-11-29 |
JP2014515382A (en) | 2014-06-30 |
ECSP13013048A (en) | 2014-01-31 |
EA201391752A1 (en) | 2014-04-30 |
ES2600636T3 (en) | 2017-02-10 |
CA2833813A1 (en) | 2012-12-06 |
AU2012264875A1 (en) | 2013-10-31 |
CR20130580A (en) | 2013-12-09 |
ZA201308395B (en) | 2014-07-30 |
BR112013030281A2 (en) | 2016-11-29 |
IL229334A0 (en) | 2014-01-30 |
IL229334A (en) | 2017-02-28 |
KR20140048137A (en) | 2014-04-23 |
AU2012264875B2 (en) | 2017-04-27 |
EP2714697A1 (en) | 2014-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012264875B2 (en) | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors | |
US8987255B2 (en) | Halogen-alkyl-1,3 oxazines as BACE1 and/or BACE2 inhibitors | |
US8404680B2 (en) | N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors | |
US9115098B2 (en) | 1,3-oxazines as BACE1 and/or BACE2 inhibitors | |
WO2012098064A1 (en) | 1,4 oxazines as bace1 and/or bace2 inhibitors | |
WO2012156284A1 (en) | 1,3-oxazines as bace1 and/or bace2 inhibitors | |
EP2694495A1 (en) | 1,4-oxazepines as bace1 and/or bace2 inhibitors | |
NZ616817B2 (en) | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as bace1 and/or bace2 inhibitors | |
NZ617507B2 (en) | Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors | |
NZ614545B2 (en) | 1,3 oxazines as bace1 and/or bace2 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12724116 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2833813 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2012264875 Country of ref document: AU Date of ref document: 20120524 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2013-000580 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13267226 Country of ref document: CO |
|
REEP | Request for entry into the european phase |
Ref document number: 2012724116 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012724116 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013003372 Country of ref document: CL Ref document number: 002577-2013 Country of ref document: PE |
|
ENP | Entry into the national phase |
Ref document number: 2014513129 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2013/013910 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 20137033959 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201391752 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201315118 Country of ref document: UA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013030281 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013030281 Country of ref document: BR Kind code of ref document: A2 Effective date: 20131126 |